US20110160261A2 - Co-solvent compositions and methods for improved delivery of dantrolene therapeutic agents - Google Patents
Co-solvent compositions and methods for improved delivery of dantrolene therapeutic agents Download PDFInfo
- Publication number
- US20110160261A2 US20110160261A2 US12/205,303 US20530308A US2011160261A2 US 20110160261 A2 US20110160261 A2 US 20110160261A2 US 20530308 A US20530308 A US 20530308A US 2011160261 A2 US2011160261 A2 US 2011160261A2
- Authority
- US
- United States
- Prior art keywords
- solution
- dantrolene sodium
- dantrolene
- solvent
- lyophilized
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 93
- 239000006184 cosolvent Substances 0.000 title claims abstract description 38
- OZOMQRBLCMDCEG-VIZOYTHASA-N 1-[(E)-[5-(4-nitrophenyl)furan-2-yl]methylideneamino]imidazolidine-2,4-dione Chemical compound C1=CC([N+](=O)[O-])=CC=C1C(O1)=CC=C1\C=N\N1C(=O)NC(=O)C1 OZOMQRBLCMDCEG-VIZOYTHASA-N 0.000 title claims description 30
- 229960001987 Dantrolene Drugs 0.000 title claims description 28
- 239000003814 drug Substances 0.000 title description 29
- 229960003710 Dantrolene Sodium Drugs 0.000 claims abstract description 141
- LTWQNYPDAUSXBC-CDJGKPBYSA-L dantrolene sodium hemiheptahydrate Chemical compound O.O.O.O.O.O.O.[Na+].[Na+].C1=CC([N+](=O)[O-])=CC=C1C(O1)=CC=C1\C=N\N1C(=O)[N-]C(=O)C1.C1=CC([N+](=O)[O-])=CC=C1C(O1)=CC=C1\C=N\N1C(=O)[N-]C(=O)C1 LTWQNYPDAUSXBC-CDJGKPBYSA-L 0.000 claims abstract description 141
- DKGAVHZHDRPRBM-UHFFFAOYSA-N t-BuOH Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 claims abstract description 117
- 238000009472 formulation Methods 0.000 claims abstract description 50
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 37
- 206010020844 Hyperthermia malignant Diseases 0.000 claims abstract description 30
- 201000007004 malignant hyperthermia Diseases 0.000 claims abstract description 30
- 239000000243 solution Substances 0.000 claims description 116
- 238000004108 freeze drying Methods 0.000 claims description 85
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 57
- 239000000047 product Substances 0.000 claims description 49
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 49
- 238000001035 drying Methods 0.000 claims description 39
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 38
- 238000002360 preparation method Methods 0.000 claims description 37
- LRHPLDYGYMQRHN-UHFFFAOYSA-N n-butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims description 33
- 239000003960 organic solvent Substances 0.000 claims description 29
- 239000002552 dosage form Substances 0.000 claims description 23
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 22
- 238000000034 method Methods 0.000 claims description 22
- 239000002904 solvent Substances 0.000 claims description 20
- FBPFZTCFMRRESA-KAZBKCHUSA-N D-Mannitol Natural products OC[C@@H](O)[C@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KAZBKCHUSA-N 0.000 claims description 19
- FBPFZTCFMRRESA-KVTDHHQDSA-N Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 19
- 239000000594 mannitol Substances 0.000 claims description 19
- 235000010355 mannitol Nutrition 0.000 claims description 19
- XEKOWRVHYACXOJ-UHFFFAOYSA-N acetic acid ethyl ester Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 18
- CSCPPACGZOOCGX-UHFFFAOYSA-N acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 18
- 239000006185 dispersion Substances 0.000 claims description 17
- 238000007710 freezing Methods 0.000 claims description 16
- 150000001875 compounds Chemical class 0.000 claims description 15
- VZGDMQKNWNREIO-UHFFFAOYSA-N Carbon tetrachloride Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 claims description 12
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 12
- 238000001816 cooling Methods 0.000 claims description 12
- -1 nitro, cyano, amino, chloro, bromo, acetyl Chemical group 0.000 claims description 12
- KXKVLQRXCPHEJC-UHFFFAOYSA-N Methyl acetate Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 claims description 10
- WEVYAHXRMPXWCK-UHFFFAOYSA-N acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 10
- 239000008176 lyophilized powder Substances 0.000 claims description 10
- 239000003795 chemical substances by application Substances 0.000 claims description 9
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 claims description 8
- 229960004926 Chlorobutanol Drugs 0.000 claims description 8
- OSASVXMJTNOKOY-UHFFFAOYSA-N Chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 claims description 8
- 239000007864 aqueous solution Substances 0.000 claims description 8
- 239000003125 aqueous solvent Substances 0.000 claims description 8
- YMWUJEATGCHHMB-UHFFFAOYSA-N methylene dichloride Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 8
- AMQJEAYHLZJPGS-UHFFFAOYSA-N n-pentanol Chemical compound CCCCCO AMQJEAYHLZJPGS-UHFFFAOYSA-N 0.000 claims description 8
- BDERNNFJNOPAEC-UHFFFAOYSA-N propanol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 claims description 8
- 239000003937 drug carrier Substances 0.000 claims description 7
- KFZMGEQAYNKOFK-UHFFFAOYSA-N iso-propanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 7
- 229960004592 isopropanol Drugs 0.000 claims description 7
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 6
- 239000003002 pH adjusting agent Substances 0.000 claims description 6
- 239000008223 sterile water Substances 0.000 claims description 6
- VBZWSGALLODQNC-UHFFFAOYSA-N Hexafluoroacetone Chemical compound FC(F)(F)C(=O)C(F)(F)F VBZWSGALLODQNC-UHFFFAOYSA-N 0.000 claims description 5
- IEJIGPNLZYLLBP-UHFFFAOYSA-N Dimethyl carbonate Chemical compound COC(=O)OC IEJIGPNLZYLLBP-UHFFFAOYSA-N 0.000 claims description 4
- WJRBRSLFGCUECM-UHFFFAOYSA-N Hydantoin Chemical compound O=C1CNC(=O)N1 WJRBRSLFGCUECM-UHFFFAOYSA-N 0.000 claims description 4
- NTIZESTWPVYFNL-UHFFFAOYSA-N Methyl isobutyl ketone Chemical compound CC(C)CC(C)=O NTIZESTWPVYFNL-UHFFFAOYSA-N 0.000 claims description 4
- HHVIBTZHLRERCL-UHFFFAOYSA-N Methylsulfonylmethane Chemical compound CS(C)(=O)=O HHVIBTZHLRERCL-UHFFFAOYSA-N 0.000 claims description 4
- 239000001257 hydrogen Substances 0.000 claims description 4
- 229910052739 hydrogen Inorganic materials 0.000 claims description 4
- 230000000087 stabilizing Effects 0.000 claims description 4
- IJDKYYCUONOPBK-UHFFFAOYSA-N 1-[[5-(2,4-dichlorophenyl)furan-2-yl]methylideneamino]imidazolidine-2,4-dione Chemical compound ClC1=CC(Cl)=CC=C1C(O1)=CC=C1C=NN1C(=O)NC(=O)C1 IJDKYYCUONOPBK-UHFFFAOYSA-N 0.000 claims description 3
- CPBZARXQRZTYGI-UHFFFAOYSA-N 3-cyclopentylpropylcyclohexane Chemical compound C1CCCCC1CCCC1CCCC1 CPBZARXQRZTYGI-UHFFFAOYSA-N 0.000 claims description 3
- KQNPFQTWMSNSAP-UHFFFAOYSA-N Isobutyric acid Chemical compound CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 claims description 3
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 3
- 229940091173 hydantoin Drugs 0.000 claims description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 3
- UXUTWFLSENWVIM-UHFFFAOYSA-N 1-[[5-(4-aminophenyl)furan-2-yl]methylideneamino]imidazolidine-2,4-dione Chemical compound C1=CC(N)=CC=C1C(O1)=CC=C1C=NN1C(=O)NC(=O)C1 UXUTWFLSENWVIM-UHFFFAOYSA-N 0.000 claims description 2
- XDICRFJOPMLLET-UHFFFAOYSA-N 1-[[5-(4-chlorophenyl)furan-2-yl]methylideneamino]imidazolidine-2,4-dione Chemical compound C1=CC(Cl)=CC=C1C(O1)=CC=C1C=NN1C(=O)NC(=O)C1 XDICRFJOPMLLET-UHFFFAOYSA-N 0.000 claims description 2
- VYLIHXCXXMSMOH-UHFFFAOYSA-N 4-[5-[(2,4-dioxoimidazolidin-1-yl)iminomethyl]furan-2-yl]benzonitrile Chemical compound O=C1NC(=O)CN1N=CC1=CC=C(C=2C=CC(=CC=2)C#N)O1 VYLIHXCXXMSMOH-UHFFFAOYSA-N 0.000 claims description 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 2
- 150000002431 hydrogen Chemical class 0.000 claims description 2
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims description 2
- QEGNUYASOUJEHD-UHFFFAOYSA-N 1,1-dimethylcyclohexane Chemical compound CC1(C)CCCCC1 QEGNUYASOUJEHD-UHFFFAOYSA-N 0.000 claims 1
- 101710031196 DRS4 Proteins 0.000 claims 1
- 239000008380 degradant Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 abstract description 16
- 238000001990 intravenous administration Methods 0.000 abstract description 12
- 238000001356 surgical procedure Methods 0.000 abstract description 6
- 239000008177 pharmaceutical agent Substances 0.000 abstract description 5
- 238000001050 pharmacotherapy Methods 0.000 abstract description 4
- 235000019441 ethanol Nutrition 0.000 description 31
- 239000008186 active pharmaceutical agent Substances 0.000 description 26
- 229940079593 drugs Drugs 0.000 description 24
- 201000010099 disease Diseases 0.000 description 19
- 235000011121 sodium hydroxide Nutrition 0.000 description 16
- 239000000969 carrier Substances 0.000 description 10
- 238000002156 mixing Methods 0.000 description 9
- 239000000843 powder Substances 0.000 description 9
- 239000007788 liquid Substances 0.000 description 8
- 238000007792 addition Methods 0.000 description 7
- 235000012970 cakes Nutrition 0.000 description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 6
- 150000001298 alcohols Chemical class 0.000 description 6
- 238000004090 dissolution Methods 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 238000001802 infusion Methods 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 239000011780 sodium chloride Substances 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 239000008215 water for injection Substances 0.000 description 6
- 241000124008 Mammalia Species 0.000 description 5
- 230000002631 hypothermal Effects 0.000 description 5
- 239000000825 pharmaceutical preparation Substances 0.000 description 5
- 150000003839 salts Chemical class 0.000 description 5
- 0 *C1=CC=C(/C=N/N2CCN([Y])C2=O)O1 Chemical compound *C1=CC=C(/C=N/N2CCN([Y])C2=O)O1 0.000 description 4
- UXUTWFLSENWVIM-FRKPEAEDSA-N 1-[(E)-[5-(4-aminophenyl)furan-2-yl]methylideneamino]imidazolidine-2,4-dione Chemical compound C1=CC(N)=CC=C1C(O1)=CC=C1\C=N\N1C(=O)NC(=O)C1 UXUTWFLSENWVIM-FRKPEAEDSA-N 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 230000001747 exhibiting Effects 0.000 description 4
- 238000005755 formation reaction Methods 0.000 description 4
- XLYOFNOQVPJJNP-ZSJDYOACSA-N heavy water Substances [2H]O[2H] XLYOFNOQVPJJNP-ZSJDYOACSA-N 0.000 description 4
- 238000011068 load Methods 0.000 description 4
- KWYUFKZDYYNOTN-UHFFFAOYSA-M potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 4
- DNIAPMSPPWPWGF-UHFFFAOYSA-N propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 4
- 239000008227 sterile water for injection Substances 0.000 description 4
- 230000001954 sterilising Effects 0.000 description 4
- 238000004659 sterilization and disinfection Methods 0.000 description 4
- 210000001519 tissues Anatomy 0.000 description 4
- 239000003981 vehicle Substances 0.000 description 4
- 206010003119 Arrhythmia Diseases 0.000 description 3
- 206010007521 Cardiac arrhythmias Diseases 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 210000002027 Muscle, Skeletal Anatomy 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- UIIMBOGNXHQVGW-UHFFFAOYSA-M buffer Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 3
- CURLTUGMZLYLDI-UHFFFAOYSA-N carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 3
- 239000001569 carbon dioxide Substances 0.000 description 3
- 229910002092 carbon dioxide Inorganic materials 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000003247 decreasing Effects 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 3
- 230000002349 favourable Effects 0.000 description 3
- 238000011049 filling Methods 0.000 description 3
- 239000012467 final product Substances 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 238000002844 melting Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000006011 modification reaction Methods 0.000 description 3
- 230000001537 neural Effects 0.000 description 3
- 230000003000 nontoxic Effects 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- GMVPRGQOIOIIMI-DWKJAMRDSA-N prostaglandin E1 Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(O)=O GMVPRGQOIOIIMI-DWKJAMRDSA-N 0.000 description 3
- KEAYESYHFKHZAL-UHFFFAOYSA-N sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- KSRLIXGNPXAZHD-HAZZGOGXSA-M sodium;3-[(E)-[5-(4-nitrophenyl)furan-2-yl]methylideneamino]-5-oxo-4H-imidazol-2-olate Chemical compound [Na+].[O-]C1=NC(=O)CN1\N=C\C1=CC=C(C=2C=CC(=CC=2)[N+]([O-])=O)O1 KSRLIXGNPXAZHD-HAZZGOGXSA-M 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- 238000000859 sublimation Methods 0.000 description 3
- 230000001629 suppression Effects 0.000 description 3
- 238000010792 warming Methods 0.000 description 3
- SEGCNGONCZQFDW-OMCISZLKSA-N 1-[(E)-[5-(4-bromophenyl)-1,3-oxazol-2-yl]methylideneamino]imidazolidine-2,4-dione Chemical compound C1=CC(Br)=CC=C1C(O1)=CN=C1\C=N\N1C(=O)NC(=O)C1 SEGCNGONCZQFDW-OMCISZLKSA-N 0.000 description 2
- 229950003578 Azumolene Drugs 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N D-sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 206010012289 Dementia Diseases 0.000 description 2
- 206010015856 Extrasystoles Diseases 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 229940088597 Hormone Drugs 0.000 description 2
- 206010020843 Hyperthermia Diseases 0.000 description 2
- ZXEKIIBDNHEJCQ-UHFFFAOYSA-N Isobutanol Chemical compound CC(C)CO ZXEKIIBDNHEJCQ-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-UUNJERMWSA-N Lactose Natural products O([C@@H]1[C@H](O)[C@H](O)[C@H](O)O[C@@H]1CO)[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1 GUBGYTABKSRVRQ-UUNJERMWSA-N 0.000 description 2
- GUBGYTABKSRVRQ-YOLKTULGSA-N Maltose Natural products O([C@@H]1[C@H](O)[C@@H](O)[C@H](O)O[C@H]1CO)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 GUBGYTABKSRVRQ-YOLKTULGSA-N 0.000 description 2
- 208000008238 Muscle Spasticity Diseases 0.000 description 2
- 208000000418 Premature Cardiac Complexe Diseases 0.000 description 2
- CZMRCDWAGMRECN-GDQSFJPYSA-N Sucrose Natural products O([C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1)[C@@]1(CO)[C@H](O)[C@@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-GDQSFJPYSA-N 0.000 description 2
- 208000003734 Supraventricular Tachycardia Diseases 0.000 description 2
- 208000001871 Tachycardia Diseases 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K Tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- 206010047281 Ventricular arrhythmia Diseases 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Vitamin C Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 238000005904 alkaline hydrolysis reaction Methods 0.000 description 2
- 229960000711 alprostadil Drugs 0.000 description 2
- 230000003042 antagnostic Effects 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 230000002605 anti-dotal Effects 0.000 description 2
- 230000000111 anti-oxidant Effects 0.000 description 2
- 239000003416 antiarrhythmic agent Substances 0.000 description 2
- 239000000729 antidote Substances 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 239000002249 anxiolytic agent Substances 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 238000004166 bioassay Methods 0.000 description 2
- 239000004067 bulking agent Substances 0.000 description 2
- 230000000747 cardiac effect Effects 0.000 description 2
- 229960000603 cefalotin Drugs 0.000 description 2
- VUFGUVLLDPOSBC-XRZFDKQNSA-M cephalothin sodium Chemical compound [Na+].N([C@H]1[C@@H]2N(C1=O)C(=C(CS2)COC(=O)C)C([O-])=O)C(=O)CC1=CC=CS1 VUFGUVLLDPOSBC-XRZFDKQNSA-M 0.000 description 2
- XDTMQSROBMDMFD-UHFFFAOYSA-N cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 239000008121 dextrose Substances 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 229920001971 elastomer Polymers 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000003193 general anesthetic agent Substances 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 230000036031 hyperthermia Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000003158 myorelaxant agent Substances 0.000 description 2
- 239000000546 pharmaceutic aid Substances 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 230000000704 physical effect Effects 0.000 description 2
- 235000011118 potassium hydroxide Nutrition 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- WONASCBDLCRVNQ-CETSFZMCSA-M sodium;3-[(E)-[5-(4-bromophenyl)-1,3-oxazol-2-yl]methylideneamino]-5-oxo-4H-imidazol-2-olate;dihydrate Chemical compound O.O.[Na+].C1=CC(Br)=CC=C1C(O1)=CN=C1\C=N\N1C(=O)[N-]C(=O)C1 WONASCBDLCRVNQ-CETSFZMCSA-M 0.000 description 2
- 239000011343 solid material Substances 0.000 description 2
- 238000005063 solubilization Methods 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 230000001225 therapeutic Effects 0.000 description 2
- 238000002076 thermal analysis method Methods 0.000 description 2
- 238000001291 vacuum drying Methods 0.000 description 2
- 230000002861 ventricular Effects 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N β-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- VHZXNQKVFDBFIK-NBBHSKLNSA-N (8R,9S,10R,13S,14S,16R)-16-fluoro-10,13-dimethyl-1,2,3,4,7,8,9,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-17-one Chemical compound C1CCC[C@]2(C)[C@H]3CC[C@](C)(C([C@H](F)C4)=O)[C@@H]4[C@@H]3CC=C21 VHZXNQKVFDBFIK-NBBHSKLNSA-N 0.000 description 1
- HUFXSDXOSHQREU-UHFFFAOYSA-N 1-[[5-(3-nitrophenyl)furan-2-yl]methylideneamino]imidazolidine-2,4-dione Chemical compound [O-][N+](=O)C1=CC=CC(C=2OC(C=NN3C(NC(=O)C3)=O)=CC=2)=C1 HUFXSDXOSHQREU-UHFFFAOYSA-N 0.000 description 1
- OXRWGVGJVIXCBV-UHFFFAOYSA-N 2-methylpropan-2-ol;sulfuric acid Chemical compound CC(C)(C)O.OS(O)(=O)=O OXRWGVGJVIXCBV-UHFFFAOYSA-N 0.000 description 1
- CWSZBVAUYPTXTG-UHFFFAOYSA-N 5-[6-[[3,4-dihydroxy-6-(hydroxymethyl)-5-methoxyoxan-2-yl]oxymethyl]-3,4-dihydroxy-5-[4-hydroxy-3-(2-hydroxyethoxy)-6-(hydroxymethyl)-5-methoxyoxan-2-yl]oxyoxan-2-yl]oxy-6-(hydroxymethyl)-2-methyloxane-3,4-diol Chemical compound O1C(CO)C(OC)C(O)C(O)C1OCC1C(OC2C(C(O)C(OC)C(CO)O2)OCCO)C(O)C(O)C(OC2C(OC(C)C(O)C2O)CO)O1 CWSZBVAUYPTXTG-UHFFFAOYSA-N 0.000 description 1
- 229960004308 ACETYLCYSTEINE Drugs 0.000 description 1
- 229940035674 ANESTHETICS Drugs 0.000 description 1
- 229940036592 ANTHELMINTICS Drugs 0.000 description 1
- 229960003965 ANTIEPILEPTICS Drugs 0.000 description 1
- 229940116904 ANTIINFLAMMATORY THERAPEUTIC RADIOPHARMACEUTICALS Drugs 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 235000006491 Acacia senegal Nutrition 0.000 description 1
- 206010000565 Acquired immunodeficiency syndrome Diseases 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Natural products NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 229960000643 Adenine Drugs 0.000 description 1
- CIDNKDMVSINJCG-GKXONYSUSA-N Annamycin Chemical compound I[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(=O)CO)C1 CIDNKDMVSINJCG-GKXONYSUSA-N 0.000 description 1
- 229940064005 Antibiotic throat preparations Drugs 0.000 description 1
- 229940083879 Antibiotics FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE Drugs 0.000 description 1
- 229940042052 Antibiotics for systemic use Drugs 0.000 description 1
- 229940075522 Antidotes Drugs 0.000 description 1
- 229940042786 Antitubercular Antibiotics Drugs 0.000 description 1
- UUSZLLQJYRSZIS-LXNNNBEUSA-N Aplidine Chemical compound CN([C@H](CC(C)C)C(=O)N[C@@H]1C(=O)N[C@@H]([C@H](CC(=O)O[C@H](C(=O)[C@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N2CCC[C@H]2C(=O)N(C)[C@@H](CC=2C=CC(OC)=CC=2)C(=O)O[C@@H]1C)C(C)C)O)[C@@H](C)CC)C(=O)[C@@H]1CCCN1C(=O)C(C)=O UUSZLLQJYRSZIS-LXNNNBEUSA-N 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 210000004204 Blood Vessels Anatomy 0.000 description 1
- CZBZUDVBLSSABA-UHFFFAOYSA-N Butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 1
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 1
- TZDYGVLLOZBPDX-UHFFFAOYSA-N C(C)(C)(C)O.C1(C(CCCC1)N)N Chemical compound C(C)(C)(C)O.C1(C(CCCC1)N)N TZDYGVLLOZBPDX-UHFFFAOYSA-N 0.000 description 1
- 210000003996 CFU-GM Anatomy 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 229940015688 Caverject Drugs 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 206010008129 Cerebral palsy Diseases 0.000 description 1
- RZZPDXZPRHQOCG-OJAKKHQRSA-N Citicoline Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(=O)OP([O-])(=O)OCC[N+](C)(C)C)O[C@H]1N1C(=O)N=C(N)C=C1 RZZPDXZPRHQOCG-OJAKKHQRSA-N 0.000 description 1
- VPUGDVKSAQVFFS-UHFFFAOYSA-N Coronene Chemical compound C1=C(C2=C34)C=CC3=CC=C(C=C3)C4=C4C3=CC=C(C=C3)C4=C2C3=C1 VPUGDVKSAQVFFS-UHFFFAOYSA-N 0.000 description 1
- 229940064701 Corticosteroid nasal preparations for topical use Drugs 0.000 description 1
- 229960001334 Corticosteroids Drugs 0.000 description 1
- RKHQGWMMUURILY-UHRZLXHJSA-N Cortivazol Chemical compound C([C@H]1[C@@H]2C[C@H]([C@]([C@@]2(C)C[C@H](O)[C@@H]1[C@@]1(C)C2)(O)C(=O)COC(C)=O)C)=C(C)C1=CC1=C2C=NN1C1=CC=CC=C1 RKHQGWMMUURILY-UHRZLXHJSA-N 0.000 description 1
- 229960002433 Cysteine Drugs 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-α-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 1
- 229940030606 DIURETICS Drugs 0.000 description 1
- 229940072185 DRUGS FOR TREATMENT OF TUBERCULOSIS Drugs 0.000 description 1
- 229940119321 Dantrium Drugs 0.000 description 1
- OZOMQRBLCMDCEG-UHFFFAOYSA-N Dantrolene Chemical compound C1=CC([N+](=O)[O-])=CC=C1C(O1)=CC=C1C=NN1C(=O)NC(=O)C1 OZOMQRBLCMDCEG-UHFFFAOYSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- CXOFVDLJLONNDW-UHFFFAOYSA-N Epinat Chemical compound N1C(=O)NC(=O)C1(C=1C=CC=CC=1)C1=CC=CC=C1 CXOFVDLJLONNDW-UHFFFAOYSA-N 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 229940005494 GENERAL ANESTHETICS Drugs 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- RWSXRVCMGQZWBV-WDSKDSINSA-N Glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 1
- 229960003180 Glutathione Drugs 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- RQFCJASXJCIDSX-UUOKFMHZSA-N Guanosine monophosphate Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O RQFCJASXJCIDSX-UUOKFMHZSA-N 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 229940093922 Gynecological Antibiotics Drugs 0.000 description 1
- 229940027278 Hetastarch Drugs 0.000 description 1
- 241001272567 Hominoidea Species 0.000 description 1
- 201000001971 Huntington's disease Diseases 0.000 description 1
- 229920001612 Hydroxyethyl starch Polymers 0.000 description 1
- 206010021113 Hypothermia Diseases 0.000 description 1
- 229940025708 Injectable Product Drugs 0.000 description 1
- 206010022114 Injury Diseases 0.000 description 1
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- 229960005015 Local anesthetics Drugs 0.000 description 1
- 229940083877 Local anesthetics for treatment of hemorrhoids and anal fissures for topical use Drugs 0.000 description 1
- 229940091250 Magnesium supplements Drugs 0.000 description 1
- FEWJPZIEWOKRBE-XIXRPRMCSA-N Mesotartaric acid Chemical compound OC(=O)[C@@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-XIXRPRMCSA-N 0.000 description 1
- 230000036740 Metabolism Effects 0.000 description 1
- 210000002161 Motor Neurons Anatomy 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010028570 Myelopathy Diseases 0.000 description 1
- 102000004868 N-methyl-D-aspartate receptors Human genes 0.000 description 1
- 108090001041 N-methyl-D-aspartate receptors Proteins 0.000 description 1
- OZOMQRBLCMDCEG-VIZOYTHASA-M O=C1CN(/N=C/C2=CC=C(C3=CC=C([N+](=O)[O-])C=C3)O2)C(=O)[N-]1.[Na+] Chemical compound O=C1CN(/N=C/C2=CC=C(C3=CC=C([N+](=O)[O-])C=C3)O2)C(=O)[N-]1.[Na+] OZOMQRBLCMDCEG-VIZOYTHASA-M 0.000 description 1
- 229940074726 OPHTHALMOLOGIC ANTIINFLAMMATORY AGENTS Drugs 0.000 description 1
- 208000003435 Optic Neuritis Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 241000283898 Ovis Species 0.000 description 1
- XNOPRXBHLZRZKH-DSZYJQQASA-N Oxytocin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@H](N)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 XNOPRXBHLZRZKH-DSZYJQQASA-N 0.000 description 1
- 241000282579 Pan Species 0.000 description 1
- 102000003982 Parathyroid hormone Human genes 0.000 description 1
- 108090000445 Parathyroid hormone Proteins 0.000 description 1
- 206010061536 Parkinson's disease Diseases 0.000 description 1
- 208000008469 Peptic Ulcer Diseases 0.000 description 1
- 229960002036 Phenytoin Drugs 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- OIGNJSKKLXVSLS-VWUMJDOOSA-N Prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
- RJKFOVLPORLFTN-STHVQZNPSA-N Progesterone Natural products O=C(C)[C@@H]1[C@@]2(C)[C@H]([C@H]3[C@@H]([C@]4(C)C(=CC(=O)CC4)CC3)CC2)CC1 RJKFOVLPORLFTN-STHVQZNPSA-N 0.000 description 1
- ZGUGWUXLJSTTMA-UHFFFAOYSA-N Promazinum Chemical compound C1=CC=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 ZGUGWUXLJSTTMA-UHFFFAOYSA-N 0.000 description 1
- 210000003742 Purkinje Fibers Anatomy 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 102100010749 RYR3 Human genes 0.000 description 1
- 108060007242 RYR3 Proteins 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 229940066293 Respiratory stimulants Drugs 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 229940075582 Sorbic Acid Drugs 0.000 description 1
- 206010061367 Spinal cord disease Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- RJKFOVLPORLFTN-LEKSSAKUSA-N Syngestrets Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 1
- 229940033663 Thimerosal Drugs 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L Thiomersal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- NLVFBUXFDBBNBW-PBSUHMDJSA-N Tobramycin Chemical compound N[C@@H]1C[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N NLVFBUXFDBBNBW-PBSUHMDJSA-N 0.000 description 1
- 229940024982 Topical Antifungal Antibiotics Drugs 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N Trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 210000001635 Urinary Tract Anatomy 0.000 description 1
- 229940029983 VITAMINS Drugs 0.000 description 1
- 229960004298 Vecuronium Bromide Drugs 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229940046009 Vitamin E Drugs 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 229940021016 Vitamin IV solution additives Drugs 0.000 description 1
- SNKAWJBJQDLSFF-YEUCEMRASA-N [2-({2,3-bis[(9Z)-octadec-9-enoyloxy]propyl phosphonato}oxy)ethyl]trimethylazanium Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC SNKAWJBJQDLSFF-YEUCEMRASA-N 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 230000002378 acidificating Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000003470 adrenal cortex hormone Substances 0.000 description 1
- 230000001058 adult Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 125000003158 alcohol group Chemical group 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229960001452 alpha-Tocopherol Acetate Drugs 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- BYHDFCISJXIVBV-YWUHCJSESA-M amoxicillin sodium Chemical compound [Na+].C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C([O-])=O)(C)C)=CC=C(O)C=C1 BYHDFCISJXIVBV-YWUHCJSESA-M 0.000 description 1
- 229960002793 amoxicillin sodium Drugs 0.000 description 1
- 239000003263 anabolic agent Substances 0.000 description 1
- 230000003444 anaesthetic Effects 0.000 description 1
- 230000003555 analeptic Effects 0.000 description 1
- 239000002269 analeptic agent Substances 0.000 description 1
- 230000000954 anitussive Effects 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 230000000507 anthelmentic Effects 0.000 description 1
- 239000000921 anthelmintic agent Substances 0.000 description 1
- 230000001396 anti-anti-diuretic Effects 0.000 description 1
- 230000002429 anti-coagulation Effects 0.000 description 1
- 230000003178 anti-diabetic Effects 0.000 description 1
- 230000003556 anti-epileptic Effects 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000002558 anti-leprotic Effects 0.000 description 1
- 230000000648 anti-parkinson Effects 0.000 description 1
- 230000001754 anti-pyretic Effects 0.000 description 1
- 230000001362 anti-vertigo Effects 0.000 description 1
- 239000000043 antiallergic agent Substances 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 239000003793 antidiarrheal agent Substances 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 239000000939 antiparkinson agent Substances 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 239000003434 antitussive agent Substances 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000002968 autonomic agent Substances 0.000 description 1
- 230000003115 biocidal Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 201000004569 blindness Diseases 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 229920005557 bromobutyl Polymers 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 230000003177 cardiotonic Effects 0.000 description 1
- 239000000496 cardiotonic agent Substances 0.000 description 1
- 239000002327 cardiovascular agent Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000004027 cells Anatomy 0.000 description 1
- 230000001413 cellular Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 230000002490 cerebral Effects 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 239000012612 commercial material Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 238000005138 cryopreservation Methods 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000004059 degradation Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000002939 deleterious Effects 0.000 description 1
- 230000001419 dependent Effects 0.000 description 1
- 230000001627 detrimental Effects 0.000 description 1
- DNTNDFLIKUKKOC-UHFFFAOYSA-N diaminomethylidene-[6-(4-ethoxycarbonylphenoxy)-6-oxohexyl]azanium;methanesulfonate Chemical compound CS([O-])(=O)=O.CCOC(=O)C1=CC=C(OC(=O)CCCCCN=C(N)[NH3+])C=C1 DNTNDFLIKUKKOC-UHFFFAOYSA-N 0.000 description 1
- 239000003866 digestant Substances 0.000 description 1
- 229910001873 dinitrogen Inorganic materials 0.000 description 1
- 239000001177 diphosphate Substances 0.000 description 1
- 239000002612 dispersion media Substances 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000002196 ecbolic Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 230000002708 enhancing Effects 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- DZGCGKFAPXFTNM-UHFFFAOYSA-N ethanol;hydron;chloride Chemical compound Cl.CCO DZGCGKFAPXFTNM-UHFFFAOYSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 230000003419 expectorant Effects 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 229950000501 gabexate Drugs 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000004083 gastrointestinal agent Substances 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- 201000002406 genetic disease Diseases 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 235000003969 glutathione Nutrition 0.000 description 1
- 125000005908 glyceryl ester group Chemical group 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 235000013928 guanylic acid Nutrition 0.000 description 1
- 230000002439 hemostatic Effects 0.000 description 1
- 239000002874 hemostatic agent Substances 0.000 description 1
- 230000003301 hydrolyzing Effects 0.000 description 1
- 230000003166 hypermetabolic Effects 0.000 description 1
- 230000002977 hyperthermial Effects 0.000 description 1
- 239000000819 hypertonic solution Substances 0.000 description 1
- 230000000147 hypnotic Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 229940079866 intestinal antibiotics Drugs 0.000 description 1
- 230000003871 intestinal function Effects 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000008141 laxative Substances 0.000 description 1
- 230000002475 laxative Effects 0.000 description 1
- 201000009673 liver disease Diseases 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 229940064003 local anesthetic throat preparations Drugs 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 235000001055 magnesium Nutrition 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000003211 malignant Effects 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 239000002609 media Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000035786 metabolism Effects 0.000 description 1
- 230000002906 microbiologic Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 230000003533 narcotic Effects 0.000 description 1
- 239000004081 narcotic agent Substances 0.000 description 1
- 210000002569 neurons Anatomy 0.000 description 1
- 230000002276 neurotropic Effects 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 229940005935 ophthalmologic Antibiotics Drugs 0.000 description 1
- 239000011368 organic material Substances 0.000 description 1
- 239000002863 oxytocic agent Substances 0.000 description 1
- 239000000199 parathyroid hormone Substances 0.000 description 1
- 229960001319 parathyroid hormone Drugs 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000000079 pharmacotherapeutic Effects 0.000 description 1
- 229960003742 phenol Drugs 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 108010049948 plitidepsin Proteins 0.000 description 1
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000004633 polyglycolic acid Substances 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 229960005205 prednisolone Drugs 0.000 description 1
- 230000002335 preservative Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 239000000186 progesterone Substances 0.000 description 1
- 229960003387 progesterone Drugs 0.000 description 1
- 239000000583 progesterone congener Substances 0.000 description 1
- 229960003598 promazine Drugs 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000000506 psychotropic Effects 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 230000002829 reduced Effects 0.000 description 1
- 239000003507 refrigerant Substances 0.000 description 1
- 239000003169 respiratory stimulant agent Substances 0.000 description 1
- 230000036633 rest Effects 0.000 description 1
- 230000001624 sedative Effects 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 210000000697 sensory organs Anatomy 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229940079827 sodium hydrogen sulfite Drugs 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- WSWCOQWTEOXDQX-UHFFFAOYSA-N sorbic acid Chemical compound CC=CC=CC(O)=O WSWCOQWTEOXDQX-UHFFFAOYSA-N 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 150000003457 sulfones Chemical class 0.000 description 1
- 150000003462 sulfoxides Chemical class 0.000 description 1
- 230000000576 supplementary Effects 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 201000010874 syndrome Diseases 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229960001367 tartaric acid Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 239000005495 thyroid hormone Substances 0.000 description 1
- 230000000699 topical Effects 0.000 description 1
- 229940083878 topical for treatment of hemorrhoids and anal fissures Corticosteroids Drugs 0.000 description 1
- 230000001960 triggered Effects 0.000 description 1
- 235000019798 tripotassium phosphate Nutrition 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 229960001322 trypsin Drugs 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 238000009834 vaporization Methods 0.000 description 1
- 239000005526 vasoconstrictor agent Substances 0.000 description 1
- 230000000261 vasodilator Effects 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- VEPSYABRBFXYIB-PWXDFCLTSA-M vecuronium bromide Chemical compound [Br-].N1([C@@H]2[C@@H](OC(C)=O)C[C@@H]3CC[C@H]4[C@@H]5C[C@@H]([C@@H]([C@]5(CC[C@@H]4[C@@]3(C)C2)C)OC(=O)C)[N+]2(C)CCCCC2)CCCCC1 VEPSYABRBFXYIB-PWXDFCLTSA-M 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 150000003700 vitamin C derivatives Chemical class 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 150000003712 vitamin E derivatives Chemical class 0.000 description 1
- 229930003231 vitamins Natural products 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Images
Definitions
- the present invention relates generally to a co-solvent system for formulation and production of a pharmaceutical agent with increased solubility.
- the present invention also provides for methods of using tert-butyl alcohol (TBA) co-solvent systems in the formulation and production of a pharmaceutical agent with low solubility.
- TSA tert-butyl alcohol
- the present invention also provides for pharmaceutical compositions made using the novel co-solvent system.
- the invention provides for a method of making a dantrolene formulation for intravenous use.
- the resulting product has the ability of rapid reconstitution of the dantrolene product, which constitutes a significant improvement in the pharmacotherapy of patients undergoing malignant hyperthermia during surgery.
- Dantrolene sodium (1-[[5-(p-nitrophenyl)furfurylidene]-amino]hydantoin sodium salt) is described in U.S. Pat. No. 3,415,821, incorporated herein by reference in its entirety. It can be used as a skeletal muscle relaxant particularly in controlling the manifestations of clinical spasticity resulting from upper neuron disorders (Physicians' Desk Reference, 36th Edition, 1982). It is also used in the prevention and treatment of malignant hyperthermia in humans (Friesen et al., Can. Anaesth. Soc. J. 26:319-321, 1979).
- dantrolene sodium prevents or reduces arrhythmia in hypothermic and normothermic warm-blooded animals.
- dantrolene sodium is effective in the treatment of supraventricular tachycardias, in suppressing slow responses in infarcted tissues and in abolishing ventricular premature beats or tachycardias originating in these tissues, and in correcting ventricular rhythm disturbances due to reentry.
- Malignant hyperthermia had a mortality rate of nearly 80 percent at the time it was identified in 1960. Treatment consisted only of cooling the patient and treating the specific symptoms, but not the underlying cause. Since 1979, the antidote drug dantrolene sodium has been available for the treatment of malignant hyperthermia and has contributed greatly to a dramatic decline in mortality. The syndrome must be identified and treated early for a successful outcome.
- Dantrolene sodium for injection comes as a dry powder that must be dissolved in sterile water prior to injection. Generally, it is supplied in small glass containers containing enough powder to give about 16 to about 20 mg of the active drug.
- MHAUS Malignant Hyperthermia Association of the United States
- the active pharmaceutical ingredient (API) (DS) undergoes slow hydrolytic decomposition in aqueous media. This degradation is accelerated at higher (alkaline) pH values and is enhanced by elevated temperatures. Thus, these conditions should be avoided as much as possible during the production of the final product (DS-IV).
- the insolubility of DS in water necessitates its dissolution at a considerably higher pH than its pKa value.
- the higher pH of its formulation requirement results in: a) the alkaline hydrolysis (loss of potency) of DS, and b) susceptibility of its solution to carbon dioxide during its introduction into vials (filling of vials).
- the atmospheric carbon dioxide (CO 2 ) appears to interact with the alkaline (e.g., NaOH) content of the filled vials resulting in the reduction of the pH of their solution resulting in a possible undesirable effect in the DS formulation.
- the above two phenomena require that the dissolution of the DS (API) at the time of its formulation process and the subsequent introduction of its solution to vials be expedited prior to the commencement of its freeze-drying.
- the present invention teaches the use of a novel organic solvent/water co-solvent system that reduces (a) freezing time of the DS-W formulation, (b) its freeze-drying time and (c) the reconstitution time of the DS freeze-dried product.
- a faster reconstitution of the DS-IV product provides a great pharmacotherapeutic advantage in the treatment of patients exhibiting the life-threatening condition of malignant hyperthermia (MH) while undergoing surgery.
- IV intravenous
- DS-IV product generally comprising from about 2.5 to about 10 mg/kg patient weight, and each reconstituted with about 60 mL of sterile water for injection (WFI)
- WFI sterile water for injection
- the number of DS-IV vials used ranges from about 10 to about 20 but can be even more.
- Cases of MH requiring as many as 36 vials of DS-IV have been recorded. The length of time to reconstitute the necessary 10-36 vials (at approximately 1 to 3 min each) creates a significant issue when considering MH death can occur in as short time as 30 min from onset.
- Organic co-solvent systems encompass a wide variety of organic solvents (examples: tert butyl alcohol, ethanol, n-propanol, n-butanol, iso-propanol, ethyl acetate, acetone, methyl acetate, methanol, carbon tetrachloride, dimethylsulfoxide, chlorobutanol, cyclohexane, and acetic acid).
- organic solvents examples: tert butyl alcohol, ethanol, n-propanol, n-butanol, iso-propanol, ethyl acetate, acetone, methyl acetate, methanol, carbon tetrachloride, dimethylsulfoxide, chlorobutanol, cyclohexane, and acetic acid).
- CaverjectTM Alpharostadil
- Pfizer sterile marketed injectable product that has been freeze-dried from a TBA-water solution.
- Table 1 lists several examples of freeze-dried preparations using co-solvent systems. TABLE 1 Examples of compounds freeze-dried with co-solvent system.
- the present invention relates generally to a co-solvent system for formulation and production of a pharmaceutical agent with increased solubility.
- This invention also relates generally to a method of freeze-drying a pharmaceutical formulation using a co-solvent system.
- the present invention also provides for methods of using tert-butyl alcohol (TBA) co-solvent systems in the formulation and production of a pharmaceutical agent with low solubility.
- TSA tert-butyl alcohol
- the present invention also provides for pharmaceutical-compositions made using the novel co-solvent system.
- the invention provides for a method of making dantrolene sodium (DS) formulations for intravenous use (DS-IV).
- DS-IV dantrolene sodium
- This substantially instantaneous reconstitution of the DS-IV product constitutes a significant improvement in the pharmacotherapy of patients undergoing malignant hyperthermia during surgery.
- this substantially complete dissolution is accomplished in less than about 30 seconds. In one embodiment, this substantially complete dissolution is accomplished in about 10 to about 20 seconds.
- the present invention provides for the production of the DS-IV product involving three (3) major steps. These are as follows:
- the present invention is also directed to stable pharmaceutical compositions of dantrolene sodium, in particular lyophilized dantrolene sodium and its use in treatment of various disease states, especially neural diseases and malignant hyperthermia and other conditions involving high fever.
- An embodiment of the invention is a pharmaceutical composition of dantrolene sodium comprising trace amounts of organic solvent after reconstitution of a lyophilized pharmaceutical composition of dantrolene sodium as described herein.
- Another embodiment of the invention is a lyophilized preparation of dantrolene sodium comprising about 0.001% to about 0.3% dantrolene sodium after reconstitution.
- Another embodiment of the invention is a lyophilized preparation of dantrolene sodium comprising about 0.01% to about 0.1% dantrolene sodium after reconstitution.
- Yet another embodiment of the invention is a lyophilized preparation of dantrolene sodium comprising about 0.015% to about 0.05% dantrolene sodium after reconstitution.
- the dosage form can be about 5 to about 50 mg of dantrolene sodium, about 10 to about 30 mg of dantrolene sodium, about 10 mg to about 20 mg of dantrolene sodium, and about 20 mg of dantrolene sodium.
- Yet another embodiment of the invention is a pharmaceutical dosage form that includes a lyophilized preparation of dantrolene sodium containing not more than about 0.05% to about 1%, preferably 0.6% to about 0.7%, DS-UV (w/w).
- dosage forms can be about 5 to about 720 mg of dantrolene sodium, about 10 to about 300 mg of dantrolene sodium, about 10 to about 100 mg of dantrolene sodium, and about 12 mg to about 22 mg of dantrolene sodium.
- the invention includes a pharmaceutical composition of dantrolene sodium including dantrolene sodium containing not more than about 5% of one or more organic solvents after reconstitution of a lyophilized pharmaceutical composition of dantrolene sodium as disclosed herein.
- the organic solvent is selected from one or more of tertiary butanol, n-propanol, n-butanol, isopropanol, ethanol, methanol, acetone, ethyl acetate, dimethyl carbonate, acetonitrile, dichloromethane, methyl ethyl ketone, methyl isobutyl ketone, 1-pentanol, methyl acetate, carbon tetrachloride, dimethyl sulfoxide, hexafluoroacetone, chlorobutanol, dimethyl sulfone, acetic acid, and cyclohexane.
- the organic solvents include one or more of ethyl, methyl, propyl, butyl alcohol.
- the organic solvent is tertiary butanol, also known as TBA, t-butanol, tert-butyl alcohol or tertiary butyl alcohol, alone or in combination with one or more additional solvents.
- the organic solvent comprises at least 20, 30, 40, 50, 60, 70, 80, 90, 95, 98 99 or more percent (v/v) alcohol in combination with one or more additional solvents.
- the organic solvent comprises at least 20, 30, 40, 50, 60, 70, 80, 90, 95, 98 99 or more percent (v/v) butanol in combination with one or more additional solvents. In another embodiment, the organic solvent comprises at least 30 percent (v/v) tertiary butanol in combination with one or more additional alcohols.
- Another embodiment of the invention is a process for manufacturing a lyophilized preparation of dantrolene sodium which includes controlling the particle size of dantrolene sodium in the final product.
- Another embodiment of the invention is a dantrolene sodium pre-lyophilization solution or dispersion comprising one or more organic solvents where the solution or dispersions include at least one stabilizing concentration of an organic solvent such that the dantrolene sodium product produced during lyophilization is capable of rapid reconstitution.
- the dantrolene sodium product is cable of substantial reconstitution in a carrier in less than about 10, 8, 5, 4, 3, 2, or 1 minute(s). In another embodiment, the dantrolene sodium product is cable of substantial reconstitution in a carrier in less than about 30 seconds. In another embodiment, the dantrolene sodium product is cable of substantial reconstitution in a carrier in less than about 20 seconds. In another embodiment, the dantrolene sodium product is cable of substantial reconstitution in a carrier in about 10-20 seconds.
- An aspect of this embodiment is the lyophilized powder produced from the pre-lyophilization solution or dispersion.
- the invention also discloses methods for preparing a dantrolene sodium lyophilized preparation that includes dissolving dantrolene sodium in a stabilizing concentration of an alcohol solvent of between about 1% to about 99.9% (v/v alcohol to form a pre-lyophilization solution; and lyophilizing the pre-lyophilization solution; wherein the dantrolene sodium lyophilized preparation made from such methods comprises an excipient.
- Alcohol concentrations include about 1% to about 99%, about 1% to about 70%, about 2% to about 60%, about 3% to about 50%, about 2% to about 40%, about 2% to about 35%. Preferred concentrations of alcohol are from about 2% to about 30%.
- the alcohols include one or more of methanol, ethanol, propanol, iso-propanol, butanol, and tertiary-butanol.
- the alcohol is tertiary-butanol (tertiary butyl alcohol or TBA).
- the concentration of tertiary-butanol is about 0.5% to about 30%.
- the concentration of tertiary-butanol is about 1% to about 20%.
- the concentration of tertiary-butanol is about 2% to about 10%.
- An aspect of this embodiment is the addition of excipients before lyophilization.
- excipients are mannitol, sodium hydroxide (NaOH) or mixtures thereof.
- the pre-lyophilized concentrations of dantrolene sodium are from about 0.1 mg/mL to about 50 mg/mL. In another embodiment, the pre-lyophilized concentrations of dantrolene sodium are from about 0.2 mg/mL to about 10 mg/mL. In another embodiment, the pre-lyophilized concentrations of dantrolene sodium are from about 0.2 mg/mL to about 5 mg/mL. In yet another embodiment, the pre-lyophilized concentrations of dantrolene sodium are from about 0.2 mg/mL to about 1 mg/mL.
- a method for preparing a dantrolene sodium lyophilized preparation comprising a) dissolving dantrolene sodium in a solution of water and organic co-solvent solution comprising between about 1% to about 99% (v/v) organic co-solvent to form a pre-lyophilization solution; and b) lyophilizing the pre-lyophilization solution.
- lyophilizing the pre-lyophilization solution comprises
- a stable and lyophilized formulation of dantrolene sodium made by the process comprising a) dissolving dantrolene sodium in a solution of water and organic co-solvent solution comprising between about 1% to about 99% (v/v) organic co-solvent to form a pre-lyophilization solution; and b) lyophilizing the pre-lyophilization solution.
- lyophilizing the pre-lyophilization solution comprises: i) freezing the pre-lyophilization solution to a temperature below about ⁇ 20° C. for a time sufficient to substantially freeze the solution; ii) drying the frozen solution at a drying temperature between about ⁇ 60° C. and about 30° C. to form a dantrolene sodium lyophilized preparation.
- lyophilizing the pre-lyophilization solution comprises: i) freezing the pre-lyophilization solution to a temperature below about ⁇ 40° C. for a time sufficient to substantially freeze the solution; ii) drying the frozen solution at a drying temperature between about ⁇ 50° C. and about 30° C. for about 1 to about 100 hours to form a dantrolene sodium lyophilized preparation.
- lyophilizing the pre-lyophilization solution comprises: i) freezing the pre-lyophilization solution to a temperature below about ⁇ 40° C. to form a frozen solution; ii) holding the frozen solution at or below ⁇ 40° C. for at least 2 hours; iii) ramping the frozen solution to a primary drying temperature between about ⁇ 40° C. and about 30° C. to form a dried solution; iv) holding for about 10 to about 70 hours; v) ramping the dried solution to a secondary drying temperature between about 20° C. and about 40° C.; and vii) holding for about 5 to about 40 hours to form a dantrolene sodium lyophilized preparation.
- the lyophilization cycle includes starting with the pre-lyophilization solution at a shelf temperature for loading of about 0° C. to about 30° C., about 5° C. to about 25° C., about 5° C. to about 15° C.
- the lyophilization cycle includes ending with unloading at about 0° C. to about 30° C., about 5° C. to about 25° C., about 5° C. to about 15° C., in a pharmaceutically acceptable container that is hermetically sealed.
- the lyophilization cycle includes wherein the pressure is about 50 to about 200 microns, about 50 to about 150 microns, about 100 to about 150 microns throughout primary drying and about 50 to about 200 microns, about 50 to about 150 microns, about 100 to about 150 microns throughout secondary drying.
- Another embodiment of the invention is the lyophilized powder or preparation obtained from the methods of preparing a dantrolene sodium lyophilized preparation disclosed herein.
- the invention also involves dantrolene sodium formulations for lyophilization that include an excipient and a stabilizing concentration of an organic solvent.
- the organic solvent further comprises an alkali.
- the pre-lyophilization solution comprises about 1 to about 1000 mg/mL excipient. In another embodiment, the pre-lyophilization solution comprises about 1 to about 500 mg/mL excipient. In another embodiment, the pre-lyophilization solution comprises about 10 to about 100 mg/mL excipient.
- One formulation includes dantrolene sodium at a concentration of about 0.01 to about 15 mg/mL, mannitol at a concentration of about 1 to about 200 mg/mL, tertiary-butyl alcohol at a concentration of about 1% to about 50% (v/v) and water.
- Another formulation includes dantrolene sodium at a concentration of about 0.05 to about 5 mg/mL, mannitol at a concentration of about 8.0 mg/mL to about 100 mg/mL, tertiary-butyl alcohol at a concentration of about 1% to about 30% (v/v) and water. Included in this embodiment of the invention are the lyophilized preparations made from such dantrolene sodium formulations.
- Included in the inventions are methods of treating a medical condition in a patient that involve administering a therapeutically effective amount of a pharmaceutical composition of the invention where the condition is amenable to treatment with the pharmaceutical composition.
- compositions or pharmaceutical preparations of the invention in the manufacture of a medicament for the treatment of a medical condition, as defined herein, in a patient that involve administering a therapeutically effective amount of a pharmaceutical composition of the invention where the condition is amenable to treatment with the pharmaceutical composition.
- compositions of the invention are in combination with one or more additional therapeutic agents where the additional agent is given prior, concurrently, or subsequent to the administration of the pharmaceutical composition of the invention.
- the invention also encompasses a pharmaceutical dosage form of dantrolene wherein the dosage form comprises a vial or other pharmaceutically acceptable container.
- Preferred concentrations of dantrolene sodium include about 1 to about 500 mg/container, about 5-50 mg/container, about 5 mg to about 20 mg/container and about 10 mg to about 20 mg/container.
- the present invention also includes pre-lyophilized pharmaceutical compositions of dantrolene sodium.
- the pre-lyophilized composition includes dantrolene sodium, mannitol, tertiary-butyl alcohol, sodium hydroxide and water.
- the active pharmaceutical compounds that can be used in the present invention include dantrolene, aminodantrolene, azumolene, and salts and mixtures thereof.
- the active pharmaceutical are dantrolene sodium, 31 ⁇ 2H 2 O, azumolene sodium, 2H 2 O and aminodantrolene sodium.
- These methods may employ the compounds of this invention in a monotherapy or in combination one or more additional therapeutic agents.
- Such combination therapies include administration of the agents in a single dosage form or in multiple dosage forms administered at the same time or at different times.
- the active pharmaceutical compound further comprises at least one additional agent selected from general anesthetics; hypnotic/sedatives/antianxiety drugs; antiepileptics; antipyretic/analgesic/anti-inflammatory agents; analeptic/antihypnotic agents; antiparkinsonian drugs; psychotropic/neurotropic drugs; cns drugs; local anesthetics; skeletal muscle relaxant; autonomic drugs; antispasodics; antivertigo drugs; sense organ drugs; cardiotonics; antiarrhythmic drugs; diuretics; antihypertensive drugs; vasoconstrictors; vasodilators; cardiovascular drugs; respiratory stimulants; antitussives; expectorant's; brochodilators; antidiarrheal drugs/drugs for controlling intestinal function; peptic ulcer remedies; stomachics/digestants; laxatives/clysters; cholagogues; gastrointestinal drugs; thyroid/parathyroid hormone drugs; anabolic steroid drugs;
- the active pharmaceutical compound is a hypertonic solution that further contains at least one additional agent selected from adenine nucleosides, nucleotides, amino acids, mannitol, vitamin C, glutathione, vitamin E, magnesium, dantrolene, corticosteroids, promazine, nicholin, 21-amino steroids, non-steroidal anti-inflammatory agents, calcium antagonists, and K-ATP channel openers.
- at least one additional agent selected from adenine nucleosides, nucleotides, amino acids, mannitol, vitamin C, glutathione, vitamin E, magnesium, dantrolene, corticosteroids, promazine, nicholin, 21-amino steroids, non-steroidal anti-inflammatory agents, calcium antagonists, and K-ATP channel openers.
- FIG. 1 shows a schematic diagram of the formulation procedure for cooling and addition of co-solvent.
- the diagram is a pictorial representation of the formulation procedure for the preparation of the rapidly reconstituted freeze-dried DS-IV product using a TBA-aqueous co-solvent system.
- Mixing and Cooling is accomplished as follows: To an aqueous (WFI) solution of mannitol containing enough of NaOH to bring the pH to 10.1-10.3 at 50° C., DS (API) is added. Mixing at 50° C. continues for 20 minutes. This is followed by a period of cooling down to 25° C. when TBA is added.
- WFI aqueous
- API API
- APT Active Pharmaceutical Ingredient
- DS Dantrolene Sodium
- DS-UV Dantrolene Sodium Intravenous
- GRAS Generally Regarded as Safe
- KOH Potassium Hydroxide
- MH Malignant Hyperthermia
- MH Sodium Hydroxide
- NaOH Tertiary Butyl Alcohol
- TSA Tertiary butanol
- TAA Tertiary butanol
- USP United States Pharmacopeia
- administration of the pharmaceutically active compounds and the pharmaceutical compositions defined herein includes systemic use, as by injection (especially parenterally), intravenous infusion, suppositories and oral administration thereof, as well as topical application of the compounds and compositions. Intravenous administration is particularly preferred in the present invention.
- “Ameliorate” or “amelioration” means a lessening of the detrimental effect or severity of the disease in the subject receiving therapy, the severity of the response being determined by means that are well known in the art.
- ком ⁇ онент herein is meant that the components of the compositions which comprise the present invention are capable of being comingled without interacting in a manner which would substantially decrease the efficacy of the pharmaceutically active compound under ordinary use conditions.
- an effective amount refers to a nontoxic but sufficient amount of the agent to provide the desired biological result. That result can be reduction and/or alleviation of the signs, symptoms, or causes of a disease, such as neural diseases and malignant hyperthermia, or any other desired alteration of a biological system. Such amounts are described below. An appropriate “effective” amount in any individual case may be determined by one of ordinary skill in the art using routine experimentation.
- excipient means the substances used to formulate active pharmaceutical ingredients (API) into pharmaceutical formulations; in a preferred embodiment, an excipient does not lower or interfere with the primary therapeutic effect of the API. Preferably, an excipient is therapeutically inert.
- excipient encompasses carriers, diluents, vehicles, solubilizers, stabilizers, bulking agents, acidic or basic pH-adjusting agents and binders. Excipients can also be those substances present in a pharmaceutical formulation as an indirect or unintended result of the manufacturing process. Preferably, excipients are approved for or considered to be safe for human and animal administration, i.e., GRAS substances (generally regarded as safe).
- the excipients include, but are not limited to, hexitols, including mannitol and the like as well as sodium or potassium hydroxides (NAOH or KOH) and mixtures thereof.
- formulation refers to the preparation of a drug, e.g., dantrolene, in a form suitable for administration to a mammalian patient, preferably a human.
- formulation can include the addition of pharmaceutically acceptable excipients, diluents, or carriers and pH adjusting agents.
- lyophilized powder or “lyophilized preparation” refers to any solid material obtained by lyophilization, i.e., freeze-drying of an aqueous solution.
- the aqueous solution may contain a non-aqueous solvent, i.e. a solution composed of aqueous and one or more non-aqueous solvent(s).
- a lyophilized preparation is one in which the solid material is obtained by freeze-drying a solution composed of aqueous and one or more non-aqueous solvents.
- the non-aqueous solvent is an alcohol.
- the non-aqueous solvent comprises at least butanol.
- the non-aqueous solvent comprises at least tert-butyl alcohol.
- organic solvent means an organic material, usually a liquid, capable of dissolving other substances.
- trace amount of an organic solvent means an amount of solvent that is equal to or below recommended levels for pharmaceutical products, for example, as recommended by ICH guidelines (International Conferences on Harmonization, Impurities—Guidelines for Residual Solvents. Q3C. Federal Register. 1997; 62(247):67377). The lower limit is the lowest amount that can be detected.
- pharmaceutically acceptable or “pharmacologically acceptable” is meant a material which is not biologically or otherwise undesirable, i.e., the material may be administered to an individual without causing any undesirable biological effects or interacting in a deleterious manner with any of the components of the composition in which it is contained.
- a “pharmaceutically acceptable carrier” is a material that is nontoxic and generally inert and does not affect the functionality of the active ingredients adversely.
- examples of pharmaceutically acceptable carriers are well known and they are sometimes referred to as dilutents, vehicles or excipients.
- the carriers may be organic or inorganic in nature.
- Examples of pharmaceutically acceptable carriers that may be present in the present lyophilized formulations may be gelatin, lactose, starch, cocoa butter, dextrose, sucrose, sorbitol, mannitol, gum acacia, alginates, cellulose, talc, magnesium stearate, polyoxyethylene sorbitan monolaurate, polyvinylpyro-lidone (PVP) and other commonly used pharmaceutical carriers.
- the pharmaceutical carrier comprises mannitol.
- the formulation may contain minor amounts of pH adjusting agents such as sodium hydroxide (NaOH) additives such as flavoring agents, coloring agents, thickening or gelling agents, emulsifiers, wetting agents, buffers, stabilizers, and preservatives such as antioxidants.
- pH adjusting agents such as sodium hydroxide (NaOH) additives such as flavoring agents, coloring agents, thickening or gelling agents, emulsifiers, wetting agents, buffers, stabilizers, and preservatives such as antioxidants.
- physiological pH or a “pH in the physiological range” is meant a pH in the range of approximately 7.2 to 8.0 inclusive, more typically in the range of approximately 7.2 to 7.6 inclusive.
- composition as used herein shall mean a composition that is made under conditions such that it is suitable for administration to humans, e.g., it is made under GMP conditions and contains pharmaceutically acceptable excipients, e.g., without limitation, stabilizers, pH adjusting agents such as NaOH, bulking agents, buffers, carriers, diluents, vehicles, solubilizers, and binders.
- pharmaceutical composition includes but is not limited to a pre-lyophilization solution or dispersion as well as a liquid form ready for injection or infusion after reconstitution of a lyophilized preparation.
- a “pharmaceutical dosage form” as used herein means the pharmaceutical compositions disclosed herein being in a container and in an amount suitable for reconstitution and administration of one or more doses, typically about 1-2, 1-3, 1-4, 1-5, 1-6, 1-10, or about 1-20 doses.
- a “pharmaceutical dosage form” as used herein means a lyophilized pharmaceutical composition disclosed herein in a container and in an amount suitable for reconstitution and delivery of one or more doses, typically about 1-2, 1-3, 1-4, 1-5, 1-10, 1-20, or about 1-30 doses.
- the pharmaceutical dosage form can comprise a vial or syringe or other suitable pharmaceutically acceptable container.
- the pharmaceutical dosage form suitable for injection or infusion use can include sterile aqueous solutions or dispersions or sterile powders comprising an active ingredient which are adapted for the extemporaneous preparation of sterile injectable or infusible solutions or dispersions.
- the ultimate dosage form should be sterile, free of endotoxins and particulates, within the USP requirements, fluid and stable under the conditions of manufacture and storage.
- the liquid carrier or vehicle can be a solvent or liquid dispersion medium comprising, for example, water, ethanol, a polyol such as glycerol, propylene glycol, or liquid polyethylene glycols and the like, vegetable oils, nontoxic glyceryl esters, and suitable mixtures thereof.
- the prevention of the growth of microorganisms can be accomplished by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, thimerosal, and the like.
- stable pharmaceutical composition any pharmaceutical composition having sufficient stability to have utility as a pharmaceutical product.
- the shelf-life or expiration can be that amount of time where the active ingredient degrades to a point below 90% purity.
- stable pharmaceutical composition includes reference to pharmaceutical compositions with specific ranges of impurities as described herein.
- the term “subject” encompasses mammals and non-mammals.
- mammals include, but are not limited to, any member of the Mammalia class: humans, non-human primates such as chimpanzees, and other apes and monkey species; farm animals such as cattle, horses, sheep, goats, swine; domestic animals such as rabbits, dogs, and cats; laboratory animals including rodents, such as rats, mice and guinea pigs, and the like.
- non-mammals include, but are not limited to, birds, fish and the like. The term does not denote a particular age or sex.
- the terms “treating” or “treatment” of a disease include preventing the disease, i.e. preventing clinical symptoms of the disease in a subject that may be exposed to, or predisposed to, the disease, but does not yet experience or display symptoms of the disease; inhibiting the disease, i.e., arresting the development of the disease or its clinical symptoms, such as by suppressing hyperthermia; or relieving the disease, i.e., causing regression of the disease or its clinical symptoms.
- vial refers to any walled container, whether rigid or flexible.
- the invention provides for stable, pharmaceutically acceptable compositions prepared from an active pharmaceutical agent.
- the invention provides formulations for the lyophilization of active pharmaceutical agents with low solubility upon reconstitution with physiological buffer or saline.
- the lyophilized powder obtained from the formulations made by the present invention is more easily reconstituted.
- the invention also provides for stable, pharmaceutically acceptable compositions prepared from dantrolene.
- the invention provides formulations for the lyophilization of dantrolene sodium.
- the lyophilized powder obtained from such formulations is more easily reconstituted than the presently available lyophilized powder of dantrolene.
- the active pharmaceutical compounds that can be used in the present invention include dantrolene, aminodantrolene, azumolene, and salts and mixtures thereof.
- the active pharmaceutical compounds are dantrolene sodium, 31 ⁇ 2H 2 O, azumolene sodium, 2H 2 O and aminodantrolene sodium.
- the present invention further provides formulations of dantrolene useful for treating various disease states, especially neural diseases and malignant hyperthermia.
- the formulations described herein can be administered alone or in combination with at least one additional therapeutic agent.
- Another aspect of the invention is conditions and means for enhancing the solubility of dantrolene sodium during the lyophilization reconstitution process.
- a lyophilized formulation of dantrolene sodium is achieved following removal of an organic solvent in water.
- the most typical example of the solvent used to prepare this formulation is alcohol.
- the alcohol is butanol.
- the alcohol is tertiary butanol (TBA).
- organic solvents can be used including ethanol, n-propanol, n-butanol, isoproponal, ethyl acetate, dimethyl carbonate, acetonitrile, dichloromethane, methyl ethyl ketone, methyl isobutyl ketone, acetone, 1-pentanol, methyl acetate, methanol, carbon tetrachloride, dimethyl sulfoxide, hexafluoroacetone, chlorobutanol, dimethyl sulfone, acetic acid, cyclohexane.
- These preceding solvents may be used individually or in combination.
- Useful solvents must form stable solutions with dantrolene sodium and must not react chemically or appreciably degrade or deactivate the API.
- the solubility of dantrolene sodium in the selected solvent must be high enough to form commercially useful concentrations of the drug in solvent.
- the solvent should be capable of being removed easily from an aqueous dispersion or solution of the drug product, e.g., through lyophilization or vacuum drying.
- a solution having a concentration of about 1-80 mg/mL is used; in another embodiment, a solution of about 0.05 to 10 mg/mL is used, in another embodiment, a solution of about 0.1 to about 3.5 mg/mL is used.
- a pharmaceutically acceptable lyophilization excipient can be dissolved in the aqueous phase during the formulation process.
- excipients useful for the present invention include, without limitation, sodium or potassium phosphate, citric acid, tartaric acid, gelatin, glycine, and carbohydrates such as lactose, sucrose, maltose, glycerin, dextrose, dextran, trehalose and hetastarch. Mannitol is a preferred excipient.
- excipients that may be used if desired include antioxidants, such as, without limitation, ascorbic acid, acetylcysteine, cysteine, sodium hydrogen sulfite, butyl-hydroxyanisole, butyl-hydroxytoluene or alpha-tocopherol acetate, or chelators and pH adjusting agents.
- antioxidants such as, without limitation, ascorbic acid, acetylcysteine, cysteine, sodium hydrogen sulfite, butyl-hydroxyanisole, butyl-hydroxytoluene or alpha-tocopherol acetate, or chelators and pH adjusting agents.
- Lyophilization can be carried out using standard equipment as used for lyophilization or vacuum drying. The cycle may be varied depending upon the equipment and facilities used for the fill/finish.
- an aqueous pre-lyophilization solution or dispersion is first formulated in a pharmaceutically acceptable compounding vessel.
- the solution is aseptically filtered into a sterile container, filled into an appropriate sized vial, partially stoppered and loaded into the lyophilizer.
- the solution is lyophilized until moisture content in the range of about 0.01 to about 8.0 percent is achieved.
- the resulting lyophilization powder can be readily reconstituted with Sterile Water for Injection, or other suitable carrier, to provide liquid formulations of dantrolene sodium, suitable for internal administration e.g., by parenteral injection.
- the reconstituted liquid formulation i.e., the pharmaceutical composition, is preferably a solution.
- the method for lyophilizing the pre-lyophilization solution comprises:
- the method for lyophilizing the pre-lyophilization solution further comprises the steps:
- the pressure is about 70 to about 130 microns throughout primary drying cycle, preferably the pressure is about 80 to about 120 microns throughout primary drying and more preferably from about 90 to about 110 microns throughout primary drying. In another embodiment of the invention, the pressure is about 90 to about 150 microns throughout secondary drying cycle, preferably the pressure is about 100 to about 140 microns throughout secondary drying and more preferably from about 110 to about 130 microns throughout secondary drying.
- the method for lyophilizing the pre-lyophilization solution comprises:
- the pre-lyophilization solution has a starting temperature above about 5° C., preferably above 15° C., to facilitate loading. In another embodiment, the pre-lyophilization solution is frozen at a temperature of about ⁇ 40° C. to about ⁇ 50° C., to form a frozen solution.
- the pre-lyophilization solution or dispersion normally is first formulated in a pharmaceutically acceptable container by: 1) adding an excipient, such as mannitol (about 0 to about 500 mg/mL) with mixing to water at ambient temperature, 2) adding an organic solvent (0.5-99.9% v/v), such as TBA to the aqueous solution with mixing at about 20-35° C., 4) adding dantrolene sodium to the desired concentration with mixing, 5) adding water to achieve the final volume, and 6) cooling the solution to a temperature of from about 10° C. to about 30° C., preferably about 25° C.
- the excipient may be added during a later step such as after adding the organic solvent.
- the pre-lyophilization solution or dispersion normally is first formulated in a pharmaceutically acceptable container by: 1) adding an excipient, such as mannitol (about 0 to about 500 mg/mL) with mixing with sterile water at ambient temperature and enough sodium hydroxide (NaOH) in 100% sterile water to bring the pH to 10.1 to 10.3° C., 2) adding dantrolene sodium to the desired concentration with mixing, 3) adding sterile water to achieve the final volume, 4) heating the solution to about 40° C. to about 70° C., preferably about 45° C. to about 60° C., more preferably about 50° C.
- an excipient such as mannitol (about 0 to about 500 mg/mL) with mixing with sterile water at ambient temperature and enough sodium hydroxide (NaOH) in 100% sterile water to bring the pH to 10.1 to 10.3° C.
- NaOH sodium hydroxide
- the excipient may be added during a later step such as after cooling the solution in step 5) or after adding the organic solvent.
- the pre-lyophilization solution or dispersion can be sterilized prior to lyophilization, sterilization is generally performed by aseptic filtration, e.g., through a 0.22 micron or less filter. Multiple sterilization filters can be used. Additional sterilization of the solution or dispersion can be achieved by other methods known in the art, e.g., radiation.
- the solution or dispersion is ready for lyophilization.
- the filtered solution will be introduced into a sterile receiving vessel, and then transferred to any suitable container or containers in which the formulation may be effectively lyophilized.
- the formulation is effectively and efficiently lyophilized in the containers in which the product is to be marketed, such as, without limitation, a vial, as described herein and as known in the art.
- the product is placed in a lyophilization chamber under a range of temperatures and then subjected to temperatures well below the product's freezing point, generally for several hours.
- the product is chilled below the freezing point of the solution preferably to about ⁇ 5° C., more preferably to about ⁇ 10° C. or lower, even more preferably to about ⁇ 20° C. or lower.
- the temperature will be at or below about ⁇ 40° C. for at least 2 hours.
- the chamber and the condenser are evacuated through vacuum pumps, the condenser surface having been previously chilled by circulating refrigerant.
- the condenser will have been chilled below the freezing point of the solution preferably to about ⁇ 40° C.
- the condenser will have been chilled to about ⁇ 45° C. or lower, in another embodiment to about ⁇ 60° C. or lower. Additionally, evacuation of the chamber should continue until a pressure of about 10 to about 600 mTorr, preferably about 50 to about 150 mTorr is obtained.
- the product composition is then warmed under vacuum in the chamber and condenser. This usually will be carried out by warming the shelves within the lyophilizer on which the product rests during the lyophilization process at a pressure ranging from about 10 to about 600 mTorr.
- the warming process will optimally take place very gradually. In one embodiment, the warming process will take place over the course of several hours.
- the product temperature is initially increased from about ⁇ 40° C. to about 20° C. and maintained for about 10-70 hours. In another embodiment, the product temperature is initially increased from about ⁇ 46° C. to about 20° C. and maintained for about 20-40 hours.
- the product temperature can be increased to a temperature to about 25° C.-40° C. over a period of 0-20 hours.
- the pressure in the chamber can be slowly released to atmospheric pressure (or slightly below) with sterile, dry-nitrogen gas (or equivalent gas). If the product composition has been lyophilized in containers such as vials, the vials can be stoppered, removed and sealed. Several representative samples can be removed for purposes of performing various physical, chemical, and microbiological tests to analyze the quality of the product.
- the lyophilized dantrolene formulation is typically marketed in pharmaceutical dosage form.
- the pharmaceutical dosage form of the present invention although typically in the form of a vial, may be any suitable container, such as ampoules, syringes, co-vials, which are capable of maintaining a sterile environment.
- Such containers can be glass or plastic, provided that the material does not interact with the dantrolene formulation.
- the closure is typically a stopper, most typically a sterile rubber stopper, preferably a bromobutyl rubber stopper, which affords a hermetic seal.
- the dantrolene lyophilization powder may be filled into containers, such as vials, or alternatively the pre-lyophilization solution can be filled into such vials and lyophilized therein, resulting in vials which directly contain the lyophilized dantrolene formulation.
- Such vials are, after filling or lyophilization of the solution therein, sealed, as with a stopper, to provide a sealed, sterile, pharmaceutical dosage form.
- a vial will contain a lyophilized powder including about 10-500 mg/vial, preferably about 100 mg/vial, dantrolene sodium and about 5 mg-3.0 g/vial, preferably about 3.0 g/vial, mannitol.
- the amount of dantrolene sodium is about 5 to about 100 mg/container, about 5-50 mg/vial, about 10 mg to about 30 mg/vial and about 10 mg to about 20 mg/vial.
- the lyophilized formulations of the present invention may be reconstituted with water, preferably Sterile Water for Injection, or other substantially sterile fluid such as co-solvents, to provide an appropriate solution of dantrolene sodium for intravenous administration.
- water preferably Sterile Water for Injection, or other substantially sterile fluid such as co-solvents, to provide an appropriate solution of dantrolene sodium for intravenous administration.
- Alcohols varied in their effect on solubility. Without wishing to be bound to any particular theory, smaller alcohols such as methanol and ethanol have less of an effect on solubility as compared with larger alcohols (tertiary-butanol and n-butanol). However, the shape of the alcohol is also important. For example tert-butanol was found to be better than iso-butanol in preventing precipitation in this system. The alcohol with the greatest effect on solubility was tertiary-butanol.
- compositions of the present invention comprise specifically defined dantrolene compounds, used in a safe and effective amount, together with a pharmaceutically acceptable carrier.
- dantrolene compounds used in the compositions of the present invention are those having the following structural formulae: wherein
- A is a member of the group consisting of furyl
- the active compound is one or more of the following compounds:
- the active pharmaceutical ingredient (API) dantrolene sodium (DS) (USP) is a hemiheptahydrate salt; 1-[5-(4-nitrophenyl) furfurylidene amino]imidazolidine-2,4-dione, containing 14.5-17.0% of water (31 ⁇ 2 moles) and has a molecular weight of 399.
- the anhydrous salt has a molecular weight of 336.
- Dantrolene sodium (USP) is an orange, odorless powder with a melting point of 279-280° C. It is completely soluble in propylene glycol, slightly soluble in ethanol and methanol, and is insoluble in H 2 O (15 mg/L). Higher solubility in water at pH 8.0 or greater is exhibited by dantrolene sodium. Its free acid form (dantrolene) is totally insoluble (mg/L), and it is a weak acid with a pKa of about 7.5. However, the extremely low solubility of the free acid prevents an accurate determination of its pKa.
- DS-IV lyophilized dantrolene sodium for intravenous injection
- the reconstituted product is administered as a rapid infusion to patients exhibiting the life-threatening condition of thermal hyperthermia during surgery.
- Dantrolene is an antagonist of the type 3 ryanodine receptor and is commonly given as the sodium salt (sodium dantrium), which is hydrated 1-[[[5-(4-nitrophenyl)-2-furanyl]methylene]amino]-2,4-imidazolidinedione sodium salt.
- Dantrolene is prescribed in the treatment of clinical spasticity resulting from upper motor neuron disorders such as spinal chord injury, cerebral palsy, stroke, or multiple sclerosis. Dantrolene is also effective in reversing the hypermetabolic process of malignant hyperthermia, a genetic disorder of skeletal muscle that is triggered by exposure to anesthetics and certain relaxants.
- dantrolene Other therapeutic uses for dantrolene are known in the art.
- Dreyer U.S. Pat. No. 5,597,809, teaches the use of NMDA-receptor antagonists, and also dantrolene, for the treatment of optic neuritis.
- U.S. Pat. No. 5,506,231 to Lipton teaches the use of dantrolene for the treatment of three conditions specifically associated with AIDS: dementia, myelopathy, and blindness.
- Dantrolene has been used clinically to treat malignant hypothermia, as it is known to reduce cellular energy requirements, creating a hypothermic environment.
- Kiyoshi Patent Abstracts of Japan (1994), publication number 06263636 discloses the use of dantrolene for treatment of cerebral nerve diseases such as geriatric dementia, Parkinson's disease and Huntington's disease.
- Non-therapeutic uses for dantrolene include cryopreservation of blood vessels. See U.S. Pat. Nos. 5,158,867; 5,149,621; 5,145,769 and 5,122,110, incorporated herein in their entirety.
- TBA Tertiary butyl alcohol
- the favorable physical properties of TBA include its high vapor pressure, low melting point (freezes completely in most freeze dryers with low expenditure of energy) and readily sublimes (increases sublimation rates) during the primary drying stage of the freeze-drying process.
- TBA possesses low toxicity as an organic solvent (permissible residual limit about the same as ethyl alcohol, i.e. ⁇ 5,000 ppm).
- TABLE 2 Physicochemical properties of TBA Property Value Formula: C4 H10 O Glass Transition ⁇ 93° C. Melting Point 25° C.
- the DS-IV product is a lyophilized (freeze-dried) powder containing approximately 16.8 mg of anhydrous dantrolene sodium (API) (DS) (equivalent to 20 mg of hydrous DS (API) containing 14.5% to 18% of moisture), 3 g of mannitol and enough NaOH to achieve a pH value of approximately 8.8 to 10.9 upon reconstitution with 60 mL of water for injection (WFI) per vial.
- API anhydrous dantrolene sodium
- WFI water for injection
- DS is highly insoluble, it must be dissolved at an alkaline environment (above its pKa 7.4 value). Since DS is susceptible to an alkaline hydrolysis, it must be dissolved as rapidly as possible during its formulation step. To achieve a rapid dissolution of DS, higher temperatures have to be utilized.
- the alkalinity (pH value), temperature and duration of heating of the liquid DS formulation play a role in the strength (percent of API) of the final lyophilized DS-IV product. The conditions may be appropriately adjusted to achieve a favorable strength (94-97%) in the final product.
- an aqueous co-solvent system may be used to facilitate the dissolution of an insoluble drug.
- an aqueous co-solvent system consisting of 5%, 10% and 20% TBA was used in the DS formulation, the drug (DS) (API) remained unsolubilized even after 90 minutes of mixing time at room temperature.
- the addition of TBA to the aqueous portion of the DS formulation did not increase the solubilization rate of DS (API) as is the case with the majority of drug formulations in which the TBA-aqueous co-solvent system is used.
- the use of the TBA shortened the freezing time of the pre-lyophilized “fill” solution, the freeze-drying time and the reconstitution of the freeze-dried cake of the DS-IV product.
- FIG. 1 shows the preferred manner by which solubilization of DS is achieved if the API (DS) is first mixed with its formulation constituents (e.g., about 3 g of mannitol and enough of NaOH in 100% sterile water to bring the pH to about 8.8 to about 11, preferably, from about 10 to about 10.5, more preferably from about 10.1 to about 10.3) at about 50° for a period of about 20 minutes.
- its formulation constituents e.g., about 3 g of mannitol and enough of NaOH in 100% sterile water to bring the pH to about 8.8 to about 11, preferably, from about 10 to about 10.5, more preferably from about 10.1 to about 10.3 at about 50° for a period of about 20 minutes.
- TBA is subsequently added at about 25° C. (See FIG. 1 ) to complete the formulation process.
- the addition of TBA at about 25° C. does not cause any undesirable loss of the strength (percent of API) of the formulation. This is substantiated by the fact that when the TBA-treated formulation was freeze-dried, the final reconstituted product of DS-IV exhibited strength of 95 ⁇ 1% (See Table 3).
- TBA solvent affects the freezing characteristics of a solution. Furthermore, it significantly impacts the crystal morphology of the ice, the drying rates, the surface area of the dried cake and reconstitution times of lyophilisates (freeze-dried cake) [2].
- the size and shape of the ice crystals depend on the nature and quantity of the organic solvents used in co-solvent system. Thermal analysis studies have been used to evaluate the various stable and metastable states which form with TBA-water systems during freezing. Adding TBA at different ratios was found to cause the formation of large needle-shaped ice crystals, which when sublimed they created a more porous and less resistant matrix which facilitated the drying process. Thus, drying times can be decreased by approximately 30-50% [3].
- the present invention reveals that the introduction of about 2% to about 20% TBA into the DS-IV formulation results in an approximate two-fold reduction in drying time of its lyophilisate.
- the increased drying rate is probably caused by the formation of needle-shaped ice crystals which create a porous structure, which in turn facilitate the mass transfer of water vapor due to decreased cake resistance and the increase in its surface area.
- a typical example of freeze-drying cycle of DS-IV product, produced with about 5% TBA aqueous co-solvent system comprises of the following segments: 1) starting with a shelf temperature of about 25° C. for loading; 2) freezing to about ⁇ 40 to ⁇ 50° C. over about 2-4 hours; 3) holding at ⁇ 45° C. for about 2-3 hours; 4) ramping to about 20° C. over about 2-3 hours; 5) holding at about 20° C. for 30-35 hours; 6) ramping to about 40° C. over about 1-2 hour; 7) holding at about 40° C. for about 5-7 hours; 8) ramping to about 30° C. over about 1-2 hours; 9) holding at about 30° C. for about 2-4 hrs.
- the pressure is about 90-110 microns throughout primary drying and 110-130 microns throughout secondary drying.
- the addition of TBA in the DS-IV formulation has reduced the total freeze-drying cycle duration by 33% (i.e., from 75 hours to about 50 hours or less).
- the recommended DS dose for treatment of MH ranges from 1 mg/kg to 10 mg/kg. If we consider that each vial containing 0.02 g of DS (API), then the above recommended doses translate to a minimum of four (4) vials to a maximum of 36 vials per MH episode.
- dantrolene sodium prevents or reduces arrhythmia in hypothermic and normothermic warm-blooded animals.
- dantrolene sodium is effective in the treatment of supraventricular tachycardias, in suppressing slow responses in infarcted tissues and in abolishing ventricular premature beats or tachycardias originating in these tissues, and in correcting ventricular rhythm disturbances due to reentry.
Abstract
The present invention provides for methods of using tert-butyl alcohol (TBA) co-solvent systems in the formulation and production of a pharmaceutical agent with low solubility. The present invention also provides for pharmaceutical compositions made using the novel co-solvent system. In one embodiment, the invention provides for a method of making dantrolene sodium (DS) formulation for intravenous use (DS-IV). This instantaneous reconstitution of the DS-IV product constitutes a significant improvement in the pharmacotherapy of patients undergoing malignant hyperthermia during surgery.
Description
- This application claims priority to U.S. Provisional Patent Application Ser. No. 60/978,626, which was filed on Oct. 9, 2007, the entirety of which is incorporated herein by reference for all purposes.
- The present invention relates generally to a co-solvent system for formulation and production of a pharmaceutical agent with increased solubility. The present invention also provides for methods of using tert-butyl alcohol (TBA) co-solvent systems in the formulation and production of a pharmaceutical agent with low solubility. The present invention also provides for pharmaceutical compositions made using the novel co-solvent system. In one embodiment, the invention provides for a method of making a dantrolene formulation for intravenous use. The resulting product has the ability of rapid reconstitution of the dantrolene product, which constitutes a significant improvement in the pharmacotherapy of patients undergoing malignant hyperthermia during surgery.
- Dantrolene sodium (1-[[5-(p-nitrophenyl)furfurylidene]-amino]hydantoin sodium salt) is described in U.S. Pat. No. 3,415,821, incorporated herein by reference in its entirety. It can be used as a skeletal muscle relaxant particularly in controlling the manifestations of clinical spasticity resulting from upper neuron disorders (Physicians' Desk Reference, 36th Edition, 1982). It is also used in the prevention and treatment of malignant hyperthermia in humans (Friesen et al., Can. Anaesth. Soc. J. 26:319-321, 1979).
- In connection with the use of dantrolene sodium in hyperthermic crisis it was observed that there was an elimination of the arrhythmias accompanying such crisis [Salata et al., Effects of Dantrolene Sodium on the Electrophysiological Properties of Canine Cardiac Purkinje Fibers, J. Pharmacol. Exp. Ther. 220(1):157-166 (Jan.) 1982], incorporated herein by reference in its entirety. Dantrolene sodium is useful as a cardiac antiarrhythmic agent in hypothermic and normothermic warm-blooded animals as described in U.S. Pat. No. 4,543,359, incorporated herein by reference in its entirety.
- It is also known that dantrolene sodium prevents or reduces arrhythmia in hypothermic and normothermic warm-blooded animals. In particular, dantrolene sodium is effective in the treatment of supraventricular tachycardias, in suppressing slow responses in infarcted tissues and in abolishing ventricular premature beats or tachycardias originating in these tissues, and in correcting ventricular rhythm disturbances due to reentry.
- Malignant hyperthermia had a mortality rate of nearly 80 percent at the time it was identified in 1960. Treatment consisted only of cooling the patient and treating the specific symptoms, but not the underlying cause. Since 1979, the antidote drug dantrolene sodium has been available for the treatment of malignant hyperthermia and has contributed greatly to a dramatic decline in mortality. The syndrome must be identified and treated early for a successful outcome.
- Dantrolene sodium for injection comes as a dry powder that must be dissolved in sterile water prior to injection. Generally, it is supplied in small glass containers containing enough powder to give about 16 to about 20 mg of the active drug.
- Although most cases of malignant hyperthermia respond to 2.5-4.0 mg/kg of dantrolene initially, some patients need significantly more to bring the episode under control. In addition, recrudescence is a possibility within the first few days of treatment. Finally, because of the need for continued treatment for at least 48 hours after malignant hyperthermia at a dose of about 1 mg/kg every 4 hours, the Malignant Hyperthermia Association of the United States (MHAUS) recommends that 36 vials be stocked.
- The active pharmaceutical ingredient (API) (DS) undergoes slow hydrolytic decomposition in aqueous media. This degradation is accelerated at higher (alkaline) pH values and is enhanced by elevated temperatures. Thus, these conditions should be avoided as much as possible during the production of the final product (DS-IV).
- The insolubility of DS in water necessitates its dissolution at a considerably higher pH than its pKa value. The higher pH of its formulation requirement results in: a) the alkaline hydrolysis (loss of potency) of DS, and b) susceptibility of its solution to carbon dioxide during its introduction into vials (filling of vials). The atmospheric carbon dioxide (CO2) appears to interact with the alkaline (e.g., NaOH) content of the filled vials resulting in the reduction of the pH of their solution resulting in a possible undesirable effect in the DS formulation. Thus, the above two phenomena require that the dissolution of the DS (API) at the time of its formulation process and the subsequent introduction of its solution to vials be expedited prior to the commencement of its freeze-drying.
- There is a significant need in the art for a satisfactory formulation of dantrolene sodium with greater solubility in a formulation that remains stable enough for practical use.
- The present invention teaches the use of a novel organic solvent/water co-solvent system that reduces (a) freezing time of the DS-W formulation, (b) its freeze-drying time and (c) the reconstitution time of the DS freeze-dried product. A faster reconstitution of the DS-IV product provides a great pharmacotherapeutic advantage in the treatment of patients exhibiting the life-threatening condition of malignant hyperthermia (MH) while undergoing surgery. On average, these patients generally require a rapid intravenous (IV) infusion of nine to ten (9-10) vials of DS-IV product, generally comprising from about 2.5 to about 10 mg/kg patient weight, and each reconstituted with about 60 mL of sterile water for injection (WFI) (See, for example, Merck Manual, 18th Edition, 2006). In many cases, the number of DS-IV vials used ranges from about 10 to about 20 but can be even more. Cases of MH requiring as many as 36 vials of DS-IV have been recorded. The length of time to reconstitute the necessary 10-36 vials (at approximately 1 to 3 min each) creates a significant issue when considering MH death can occur in as short time as 30 min from onset.
- Organic co-solvent systems encompass a wide variety of organic solvents (examples: tert butyl alcohol, ethanol, n-propanol, n-butanol, iso-propanol, ethyl acetate, acetone, methyl acetate, methanol, carbon tetrachloride, dimethylsulfoxide, chlorobutanol, cyclohexane, and acetic acid).
- The formulation of Caverject™ (Alprostadil) (Pfizer) is an example of sterile marketed injectable product that has been freeze-dried from a TBA-water solution. Table 1 lists several examples of freeze-dried preparations using co-solvent systems.
TABLE 1 Examples of compounds freeze-dried with co-solvent system. Drug Co-solvent System Reference Alprostadil 20% v/v tert- Teagarden (CAVERJECT ® S.Po.) butanol/water et al., 1998a Aplidine 40% v/v tert- Nuijen et butanol/water al., 2000 Amoxicillin sodium 20% v/v tert- Tico Grau butanol/water et al., 1988 Gentamicin sulfate tert-Butanol/water Baldi et al., 1994 N-Cyclodexyl-N-methyl-4- 50% v/v tert- Benjamin (2-oxo-1,2,3,5- butanol/water and Visor, tetrahydroimidazo-[2.1-b] 1989 quinazolin-7-yl) oxobutyranide with ascorbic acid Cyclohexane 1.2-diamine tert-Butanol Tanno et Pi(II) al., 1990 complex Fructose-1.6-diphosphate tert-Butanol/water Sullivan and Marangos, 1998 Annamycin tert-Butanol/dimethyl Zou et al., sulfixide/water 1999 Cephalothin sodium 5% w/w isopropyl Koyama alcohol/water et al., 1988 Cephalothin sodium 4% ethanol, 4% Cise and methanol or 4% Roy, acetone/water 1981 Prednisolone Carbon tetrachloride/ DeLuca et acetate/polyglycolic acid hexafluoroacetone al., 1989a sesquihydrate Gabexate mesylate Ethanol/water Kamijo et al., 1987 Piraubidin hydrochloride Ethanol/water Kaneko et al., 1993 Progesterone, coronene, Chlorobutanol Tesconi et fluasterone, phenytoin hemihydrate/Dimethyl al., 1999 sulfone Poly (lactide-co-glycolide) Acetic acid Meredith et al., 1996 Dioleoylphosphatidylcholine Cyclohexane Felgner and dioleoylphosphatidyl and glycerol Eppstein, 1991 Vecuroniumbromide Acetonitrile Jansen, 1997 Bovine pancreatic trypsin Dimethyl Desai and inhibitor sulfoxide/1% water Klibanov, 1995 - The present invention relates generally to a co-solvent system for formulation and production of a pharmaceutical agent with increased solubility. This invention also relates generally to a method of freeze-drying a pharmaceutical formulation using a co-solvent system.
- The present invention also provides for methods of using tert-butyl alcohol (TBA) co-solvent systems in the formulation and production of a pharmaceutical agent with low solubility. The present invention also provides for pharmaceutical-compositions made using the novel co-solvent system.
- In one embodiment, the invention provides for a method of making dantrolene sodium (DS) formulations for intravenous use (DS-IV). This substantially instantaneous reconstitution of the DS-IV product constitutes a significant improvement in the pharmacotherapy of patients undergoing malignant hyperthermia during surgery. In one embodiment, this substantially complete dissolution is accomplished in less than about 30 seconds. In one embodiment, this substantially complete dissolution is accomplished in about 10 to about 20 seconds.
- In one embodiment, the present invention provides for the production of the DS-IV product involving three (3) major steps. These are as follows:
- 1. Formulation of the active pharmaceutical ingredient (API) dantrolene sodium at an alkaline pH.
- 2. Addition of a co-solvent to make the DS solution; and filling the vials containing the solution (“fill” solution) to be lyophilized.
- 3. A lyophilization cycle of the DS solution to produce the freeze-dried sterile DS-IV product.
- The present invention is also directed to stable pharmaceutical compositions of dantrolene sodium, in particular lyophilized dantrolene sodium and its use in treatment of various disease states, especially neural diseases and malignant hyperthermia and other conditions involving high fever.
- An embodiment of the invention is a pharmaceutical composition of dantrolene sodium comprising trace amounts of organic solvent after reconstitution of a lyophilized pharmaceutical composition of dantrolene sodium as described herein.
- Another embodiment of the invention is a lyophilized preparation of dantrolene sodium comprising about 0.001% to about 0.3% dantrolene sodium after reconstitution. Another embodiment of the invention is a lyophilized preparation of dantrolene sodium comprising about 0.01% to about 0.1% dantrolene sodium after reconstitution. Yet another embodiment of the invention is a lyophilized preparation of dantrolene sodium comprising about 0.015% to about 0.05% dantrolene sodium after reconstitution.
- In preferred aspects of the invention, the dosage form can be about 5 to about 50 mg of dantrolene sodium, about 10 to about 30 mg of dantrolene sodium, about 10 mg to about 20 mg of dantrolene sodium, and about 20 mg of dantrolene sodium.
- Yet another embodiment of the invention is a pharmaceutical dosage form that includes a lyophilized preparation of dantrolene sodium containing not more than about 0.05% to about 1%, preferably 0.6% to about 0.7%, DS-UV (w/w). In certain embodiments, dosage forms can be about 5 to about 720 mg of dantrolene sodium, about 10 to about 300 mg of dantrolene sodium, about 10 to about 100 mg of dantrolene sodium, and about 12 mg to about 22 mg of dantrolene sodium.
- In still another embodiment, the invention includes a pharmaceutical composition of dantrolene sodium including dantrolene sodium containing not more than about 5% of one or more organic solvents after reconstitution of a lyophilized pharmaceutical composition of dantrolene sodium as disclosed herein.
- In different aspects of this embodiment, the organic solvent is selected from one or more of tertiary butanol, n-propanol, n-butanol, isopropanol, ethanol, methanol, acetone, ethyl acetate, dimethyl carbonate, acetonitrile, dichloromethane, methyl ethyl ketone, methyl isobutyl ketone, 1-pentanol, methyl acetate, carbon tetrachloride, dimethyl sulfoxide, hexafluoroacetone, chlorobutanol, dimethyl sulfone, acetic acid, and cyclohexane.
- In one specific embodiment, the organic solvents include one or more of ethyl, methyl, propyl, butyl alcohol. In another embodiment, the organic solvent is tertiary butanol, also known as TBA, t-butanol, tert-butyl alcohol or tertiary butyl alcohol, alone or in combination with one or more additional solvents. In another embodiment, the organic solvent comprises at least 20, 30, 40, 50, 60, 70, 80, 90, 95, 98 99 or more percent (v/v) alcohol in combination with one or more additional solvents. In another embodiment, the organic solvent comprises at least 20, 30, 40, 50, 60, 70, 80, 90, 95, 98 99 or more percent (v/v) butanol in combination with one or more additional solvents. In another embodiment, the organic solvent comprises at least 30 percent (v/v) tertiary butanol in combination with one or more additional alcohols.
- Another embodiment of the invention is a process for manufacturing a lyophilized preparation of dantrolene sodium which includes controlling the particle size of dantrolene sodium in the final product.
- Another embodiment of the invention is a dantrolene sodium pre-lyophilization solution or dispersion comprising one or more organic solvents where the solution or dispersions include at least one stabilizing concentration of an organic solvent such that the dantrolene sodium product produced during lyophilization is capable of rapid reconstitution.
- In one embodiment, the dantrolene sodium product is cable of substantial reconstitution in a carrier in less than about 10, 8, 5, 4, 3, 2, or 1 minute(s). In another embodiment, the dantrolene sodium product is cable of substantial reconstitution in a carrier in less than about 30 seconds. In another embodiment, the dantrolene sodium product is cable of substantial reconstitution in a carrier in less than about 20 seconds. In another embodiment, the dantrolene sodium product is cable of substantial reconstitution in a carrier in about 10-20 seconds.
- An aspect of this embodiment is the lyophilized powder produced from the pre-lyophilization solution or dispersion.
- The invention also discloses methods for preparing a dantrolene sodium lyophilized preparation that includes dissolving dantrolene sodium in a stabilizing concentration of an alcohol solvent of between about 1% to about 99.9% (v/v alcohol to form a pre-lyophilization solution; and lyophilizing the pre-lyophilization solution; wherein the dantrolene sodium lyophilized preparation made from such methods comprises an excipient.
- Other alcohol concentrations include about 1% to about 99%, about 1% to about 70%, about 2% to about 60%, about 3% to about 50%, about 2% to about 40%, about 2% to about 35%. Preferred concentrations of alcohol are from about 2% to about 30%.
- In one embodiment, the alcohols include one or more of methanol, ethanol, propanol, iso-propanol, butanol, and tertiary-butanol. In another embodiment, the alcohol is tertiary-butanol (tertiary butyl alcohol or TBA). In another embodiment, the concentration of tertiary-butanol is about 0.5% to about 30%. In another embodiment, the concentration of tertiary-butanol is about 1% to about 20%. In another embodiment, the concentration of tertiary-butanol is about 2% to about 10%. An aspect of this embodiment is the addition of excipients before lyophilization. In one embodiment, excipients are mannitol, sodium hydroxide (NaOH) or mixtures thereof.
- In one embodiment, the pre-lyophilized concentrations of dantrolene sodium are from about 0.1 mg/mL to about 50 mg/mL. In another embodiment, the pre-lyophilized concentrations of dantrolene sodium are from about 0.2 mg/mL to about 10 mg/mL. In another embodiment, the pre-lyophilized concentrations of dantrolene sodium are from about 0.2 mg/mL to about 5 mg/mL. In yet another embodiment, the pre-lyophilized concentrations of dantrolene sodium are from about 0.2 mg/mL to about 1 mg/mL.
- In one embodiment of the invention, there is provided a method for preparing a dantrolene sodium lyophilized preparation comprising a) dissolving dantrolene sodium in a solution of water and organic co-solvent solution comprising between about 1% to about 99% (v/v) organic co-solvent to form a pre-lyophilization solution; and b) lyophilizing the pre-lyophilization solution.
- In another embodiment, lyophilizing the pre-lyophilization solution comprises
- i) cooling the pre-lyophilization solution to a temperature capable of forming a frozen solution;
- ii) holding the frozen solution a temperature capable of forming a frozen solution, for a time sufficient to substantially freeze the solutions;
- iii) ramping the frozen solution to a primary drying temperature;
- iv) holding at a primary drying temperature at a temperature and for a time sufficient to form a substantially dried lyophilized product;
- v) optionally ramping the dried solution to a secondary drying temperature; and
- vi) optionally holding at the secondary drying temperature at a temperature and for a time sufficient to form a substantially dried dantrolene sodium lyophilized preparation.
- In another embodiment of the invention, there is provided a stable and lyophilized formulation of dantrolene sodium made by the process comprising a) dissolving dantrolene sodium in a solution of water and organic co-solvent solution comprising between about 1% to about 99% (v/v) organic co-solvent to form a pre-lyophilization solution; and b) lyophilizing the pre-lyophilization solution.
- In another embodiment, lyophilizing the pre-lyophilization solution comprises: i) freezing the pre-lyophilization solution to a temperature below about −20° C. for a time sufficient to substantially freeze the solution; ii) drying the frozen solution at a drying temperature between about −60° C. and about 30° C. to form a dantrolene sodium lyophilized preparation.
- In another embodiment, lyophilizing the pre-lyophilization solution comprises: i) freezing the pre-lyophilization solution to a temperature below about −40° C. for a time sufficient to substantially freeze the solution; ii) drying the frozen solution at a drying temperature between about −50° C. and about 30° C. for about 1 to about 100 hours to form a dantrolene sodium lyophilized preparation.
- In another embodiment, lyophilizing the pre-lyophilization solution comprises: i) freezing the pre-lyophilization solution to a temperature below about −40° C. to form a frozen solution; ii) holding the frozen solution at or below −40° C. for at least 2 hours; iii) ramping the frozen solution to a primary drying temperature between about −40° C. and about 30° C. to form a dried solution; iv) holding for about 10 to about 70 hours; v) ramping the dried solution to a secondary drying temperature between about 20° C. and about 40° C.; and vii) holding for about 5 to about 40 hours to form a dantrolene sodium lyophilized preparation.
- In another embodiment, the lyophilization cycle includes starting with the pre-lyophilization solution at a shelf temperature for loading of about 0° C. to about 30° C., about 5° C. to about 25° C., about 5° C. to about 15° C.
- In another embodiment, the lyophilization cycle includes ending with unloading at about 0° C. to about 30° C., about 5° C. to about 25° C., about 5° C. to about 15° C., in a pharmaceutically acceptable container that is hermetically sealed.
- In another embodiment, the lyophilization cycle includes wherein the pressure is about 50 to about 200 microns, about 50 to about 150 microns, about 100 to about 150 microns throughout primary drying and about 50 to about 200 microns, about 50 to about 150 microns, about 100 to about 150 microns throughout secondary drying.
- Another embodiment of the invention is the lyophilized powder or preparation obtained from the methods of preparing a dantrolene sodium lyophilized preparation disclosed herein.
- The invention also involves dantrolene sodium formulations for lyophilization that include an excipient and a stabilizing concentration of an organic solvent. In one embodiment, the organic solvent further comprises an alkali. In one embodiment, the pre-lyophilization solution comprises about 1 to about 1000 mg/mL excipient. In another embodiment, the pre-lyophilization solution comprises about 1 to about 500 mg/mL excipient. In another embodiment, the pre-lyophilization solution comprises about 10 to about 100 mg/mL excipient. One formulation includes dantrolene sodium at a concentration of about 0.01 to about 15 mg/mL, mannitol at a concentration of about 1 to about 200 mg/mL, tertiary-butyl alcohol at a concentration of about 1% to about 50% (v/v) and water. Another formulation includes dantrolene sodium at a concentration of about 0.05 to about 5 mg/mL, mannitol at a concentration of about 8.0 mg/mL to about 100 mg/mL, tertiary-butyl alcohol at a concentration of about 1% to about 30% (v/v) and water. Included in this embodiment of the invention are the lyophilized preparations made from such dantrolene sodium formulations.
- Included in the inventions are methods of treating a medical condition in a patient that involve administering a therapeutically effective amount of a pharmaceutical composition of the invention where the condition is amenable to treatment with the pharmaceutical composition.
- Included in the inventions are the use of the pharmaceutical compositions or pharmaceutical preparations of the invention in the manufacture of a medicament for the treatment of a medical condition, as defined herein, in a patient that involve administering a therapeutically effective amount of a pharmaceutical composition of the invention where the condition is amenable to treatment with the pharmaceutical composition.
- Also included in the invention are methods of treating in which the pharmaceutical compositions of the invention are in combination with one or more additional therapeutic agents where the additional agent is given prior, concurrently, or subsequent to the administration of the pharmaceutical composition of the invention.
- The invention also encompasses a pharmaceutical dosage form of dantrolene wherein the dosage form comprises a vial or other pharmaceutically acceptable container. Preferred concentrations of dantrolene sodium include about 1 to about 500 mg/container, about 5-50 mg/container, about 5 mg to about 20 mg/container and about 10 mg to about 20 mg/container.
- The present invention also includes pre-lyophilized pharmaceutical compositions of dantrolene sodium. In one embodiment the pre-lyophilized composition includes dantrolene sodium, mannitol, tertiary-butyl alcohol, sodium hydroxide and water.
- In one embodiment, the active pharmaceutical compounds that can be used in the present invention include dantrolene, aminodantrolene, azumolene, and salts and mixtures thereof. In one embodiment, the active pharmaceutical are dantrolene sodium, 3½H2O, azumolene sodium, 2H2O and aminodantrolene sodium.
- These methods may employ the compounds of this invention in a monotherapy or in combination one or more additional therapeutic agents. Such combination therapies include administration of the agents in a single dosage form or in multiple dosage forms administered at the same time or at different times.
- In another embodiment, the active pharmaceutical compound further comprises at least one additional agent selected from general anesthetics; hypnotic/sedatives/antianxiety drugs; antiepileptics; antipyretic/analgesic/anti-inflammatory agents; analeptic/antihypnotic agents; antiparkinsonian drugs; psychotropic/neurotropic drugs; cns drugs; local anesthetics; skeletal muscle relaxant; autonomic drugs; antispasodics; antivertigo drugs; sense organ drugs; cardiotonics; antiarrhythmic drugs; diuretics; antihypertensive drugs; vasoconstrictors; vasodilators; cardiovascular drugs; respiratory stimulants; antitussives; expectorant's; brochodilators; antidiarrheal drugs/drugs for controlling intestinal function; peptic ulcer remedies; stomachics/digestants; laxatives/clysters; cholagogues; gastrointestinal drugs; thyroid/parathyroid hormone drugs; anabolic steroid drugs; corticoid drugs; male hormone drugs; estrogen/progestin drugs; hormone drugs; urinary tract drugs; oxytocics; vitamins; hemostatics; anticoagulants; liver disease remedies; antidotes; arthrifuges; antidiabetics; metabolism drugs; antitumor drugs; antiallergic agents; antibiotics; sulfa drugs; antituberculosis drugs; antileprotics; synthetic antimicrobial agents; antiviral agents; chemotherapeutic drugs; anthelmintics; and narcotics.
- In another embodiment, the active pharmaceutical compound is a hypertonic solution that further contains at least one additional agent selected from adenine nucleosides, nucleotides, amino acids, mannitol, vitamin C, glutathione, vitamin E, magnesium, dantrolene, corticosteroids, promazine, nicholin, 21-amino steroids, non-steroidal anti-inflammatory agents, calcium antagonists, and K-ATP channel openers.
- These and other embodiments of the invention are described herein below or are evident to persons of ordinary skill in the art based on the following disclosures.
- The above summary of the present invention is not intended to describe each embodiment or every implementation of the present invention. Advantages and attainments, together with a more complete understanding of the invention, will become apparent and appreciated by referring to the following detailed description and claims taken in conjunction with the accompanying drawings.
- This invention, as defined in the claims, can be better understood with reference to the following drawings:
-
FIG. 1 shows a schematic diagram of the formulation procedure for cooling and addition of co-solvent. The diagram is a pictorial representation of the formulation procedure for the preparation of the rapidly reconstituted freeze-dried DS-IV product using a TBA-aqueous co-solvent system. Mixing and Cooling is accomplished as follows: To an aqueous (WFI) solution of mannitol containing enough of NaOH to bring the pH to 10.1-10.3 at 50° C., DS (API) is added. Mixing at 50° C. continues for 20 minutes. This is followed by a period of cooling down to 25° C. when TBA is added. - In the following description of the illustrated embodiments, references are made to the accompanying drawings, which form a part hereof, and in which is shown by way of illustration various embodiments in which the invention may be practiced. It is to be understood that other embodiments may be utilized and structural and functional changes may be made without departing from the scope of the present invention.
- Before the present methods and compositions are described, it is to be understood that this invention is not limited to the specific methodology, devices, formulations, and compositions described as such may, of course, vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to limit the scope of the present invention, which will be limited only by the appended claims.
- It must be noted that as used herein and in the appended claims, the singular forms “a”, “and”, and “the” include plural referents unless the context clearly dictates otherwise.
- Unless defined otherwise, all technical and scientific terms used herein have the same meanings as commonly understood by one of ordinary skill in the art to which this invention belongs. Although any methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, the preferred methods, devices, and materials are now described. All references, publications, patents, patent applications, and commercial materials mentioned herein are incorporated herein by reference for all purposes including for describing and disclosing the cell lines, vectors, and methodologies which are reported in the publications which might be used in connection with the invention. Nothing herein is to be construed as an admission that the invention is not entitled to antedate such disclosure by virtue of prior invention.
- In order to provide a clear and consistent understanding of the specification and claims, including the scope to be given such terms, the following definitions are provided:
- The specification contains the following abbreviations: Active Pharmaceutical Ingredient (APT), Dantrolene Sodium (DS), Dantrolene Sodium Intravenous (DS-UV), Generally Regarded as Safe (GRAS), Potassium Hydroxide (KOH), Malignant Hyperthermia (MH), Sodium Hydroxide (NaOH), Tertiary Butyl Alcohol, t-butanol, tertiary butanol, or tert-butyl alcohol (TBA), and United States Pharmacopeia (USP).
- The term “administration” of the pharmaceutically active compounds and the pharmaceutical compositions defined herein includes systemic use, as by injection (especially parenterally), intravenous infusion, suppositories and oral administration thereof, as well as topical application of the compounds and compositions. Intravenous administration is particularly preferred in the present invention.
- “Ameliorate” or “amelioration” means a lessening of the detrimental effect or severity of the disease in the subject receiving therapy, the severity of the response being determined by means that are well known in the art.
- By “compatible” herein is meant that the components of the compositions which comprise the present invention are capable of being comingled without interacting in a manner which would substantially decrease the efficacy of the pharmaceutically active compound under ordinary use conditions.
- The terms “effective amount” or “pharmaceutically effective amount” refer to a nontoxic but sufficient amount of the agent to provide the desired biological result. That result can be reduction and/or alleviation of the signs, symptoms, or causes of a disease, such as neural diseases and malignant hyperthermia, or any other desired alteration of a biological system. Such amounts are described below. An appropriate “effective” amount in any individual case may be determined by one of ordinary skill in the art using routine experimentation.
- As used herein, the term “excipient” means the substances used to formulate active pharmaceutical ingredients (API) into pharmaceutical formulations; in a preferred embodiment, an excipient does not lower or interfere with the primary therapeutic effect of the API. Preferably, an excipient is therapeutically inert. The term “excipient” encompasses carriers, diluents, vehicles, solubilizers, stabilizers, bulking agents, acidic or basic pH-adjusting agents and binders. Excipients can also be those substances present in a pharmaceutical formulation as an indirect or unintended result of the manufacturing process. Preferably, excipients are approved for or considered to be safe for human and animal administration, i.e., GRAS substances (generally regarded as safe). GRAS substances are listed by the Food and Drug administration in the Code of Federal Regulations (CFR) at 21 CFR 182 and 21 CFR 184, incorporated herein by reference. In one embodiment, the excipients include, but are not limited to, hexitols, including mannitol and the like as well as sodium or potassium hydroxides (NAOH or KOH) and mixtures thereof.
- As used herein, the terms “formulate” refers to the preparation of a drug, e.g., dantrolene, in a form suitable for administration to a mammalian patient, preferably a human. Thus, “formulation” can include the addition of pharmaceutically acceptable excipients, diluents, or carriers and pH adjusting agents.
- As used herein, the term “lyophilized powder” or “lyophilized preparation” refers to any solid material obtained by lyophilization, i.e., freeze-drying of an aqueous solution. The aqueous solution may contain a non-aqueous solvent, i.e. a solution composed of aqueous and one or more non-aqueous solvent(s). In one embodiment, a lyophilized preparation is one in which the solid material is obtained by freeze-drying a solution composed of aqueous and one or more non-aqueous solvents. In one embodiment, the non-aqueous solvent is an alcohol. In one specific embodiment, the non-aqueous solvent comprises at least butanol. In one specific embodiment, the non-aqueous solvent comprises at least tert-butyl alcohol.
- The term “organic solvent” means an organic material, usually a liquid, capable of dissolving other substances. As used herein, “trace amount of an organic solvent” means an amount of solvent that is equal to or below recommended levels for pharmaceutical products, for example, as recommended by ICH guidelines (International Conferences on Harmonization, Impurities—Guidelines for Residual Solvents. Q3C. Federal Register. 1997; 62(247):67377). The lower limit is the lowest amount that can be detected.
- By “pharmaceutically acceptable” or “pharmacologically acceptable” is meant a material which is not biologically or otherwise undesirable, i.e., the material may be administered to an individual without causing any undesirable biological effects or interacting in a deleterious manner with any of the components of the composition in which it is contained.
- As used herein, a “pharmaceutically acceptable carrier” is a material that is nontoxic and generally inert and does not affect the functionality of the active ingredients adversely. Examples of pharmaceutically acceptable carriers are well known and they are sometimes referred to as dilutents, vehicles or excipients. The carriers may be organic or inorganic in nature. Examples of pharmaceutically acceptable carriers that may be present in the present lyophilized formulations may be gelatin, lactose, starch, cocoa butter, dextrose, sucrose, sorbitol, mannitol, gum acacia, alginates, cellulose, talc, magnesium stearate, polyoxyethylene sorbitan monolaurate, polyvinylpyro-lidone (PVP) and other commonly used pharmaceutical carriers. In one embodiment, the pharmaceutical carrier comprises mannitol. In addition, the formulation may contain minor amounts of pH adjusting agents such as sodium hydroxide (NaOH) additives such as flavoring agents, coloring agents, thickening or gelling agents, emulsifiers, wetting agents, buffers, stabilizers, and preservatives such as antioxidants.
- By “physiological pH” or a “pH in the physiological range” is meant a pH in the range of approximately 7.2 to 8.0 inclusive, more typically in the range of approximately 7.2 to 7.6 inclusive.
- The term “pharmaceutical composition” as used herein shall mean a composition that is made under conditions such that it is suitable for administration to humans, e.g., it is made under GMP conditions and contains pharmaceutically acceptable excipients, e.g., without limitation, stabilizers, pH adjusting agents such as NaOH, bulking agents, buffers, carriers, diluents, vehicles, solubilizers, and binders. As used herein pharmaceutical composition includes but is not limited to a pre-lyophilization solution or dispersion as well as a liquid form ready for injection or infusion after reconstitution of a lyophilized preparation.
- A “pharmaceutical dosage form” as used herein means the pharmaceutical compositions disclosed herein being in a container and in an amount suitable for reconstitution and administration of one or more doses, typically about 1-2, 1-3, 1-4, 1-5, 1-6, 1-10, or about 1-20 doses. Preferably, a “pharmaceutical dosage form” as used herein means a lyophilized pharmaceutical composition disclosed herein in a container and in an amount suitable for reconstitution and delivery of one or more doses, typically about 1-2, 1-3, 1-4, 1-5, 1-10, 1-20, or about 1-30 doses. The pharmaceutical dosage form can comprise a vial or syringe or other suitable pharmaceutically acceptable container. The pharmaceutical dosage form suitable for injection or infusion use can include sterile aqueous solutions or dispersions or sterile powders comprising an active ingredient which are adapted for the extemporaneous preparation of sterile injectable or infusible solutions or dispersions. In all cases, the ultimate dosage form should be sterile, free of endotoxins and particulates, within the USP requirements, fluid and stable under the conditions of manufacture and storage. The liquid carrier or vehicle can be a solvent or liquid dispersion medium comprising, for example, water, ethanol, a polyol such as glycerol, propylene glycol, or liquid polyethylene glycols and the like, vegetable oils, nontoxic glyceryl esters, and suitable mixtures thereof. The prevention of the growth of microorganisms can be accomplished by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, thimerosal, and the like.
- By “stable pharmaceutical composition” is meant any pharmaceutical composition having sufficient stability to have utility as a pharmaceutical product. The shelf-life or expiration can be that amount of time where the active ingredient degrades to a point below 90% purity. For purposes of the present invention stable pharmaceutical composition includes reference to pharmaceutical compositions with specific ranges of impurities as described herein.
- As used herein, the term “subject” encompasses mammals and non-mammals. Examples of mammals include, but are not limited to, any member of the Mammalia class: humans, non-human primates such as chimpanzees, and other apes and monkey species; farm animals such as cattle, horses, sheep, goats, swine; domestic animals such as rabbits, dogs, and cats; laboratory animals including rodents, such as rats, mice and guinea pigs, and the like. Examples of non-mammals include, but are not limited to, birds, fish and the like. The term does not denote a particular age or sex.
- As used herein, the terms “treating” or “treatment” of a disease include preventing the disease, i.e. preventing clinical symptoms of the disease in a subject that may be exposed to, or predisposed to, the disease, but does not yet experience or display symptoms of the disease; inhibiting the disease, i.e., arresting the development of the disease or its clinical symptoms, such as by suppressing hyperthermia; or relieving the disease, i.e., causing regression of the disease or its clinical symptoms.
- As used herein, the term “vial” refers to any walled container, whether rigid or flexible.
- General
- The invention provides for stable, pharmaceutically acceptable compositions prepared from an active pharmaceutical agent. In particular, the invention provides formulations for the lyophilization of active pharmaceutical agents with low solubility upon reconstitution with physiological buffer or saline. The lyophilized powder obtained from the formulations made by the present invention is more easily reconstituted.
- The invention also provides for stable, pharmaceutically acceptable compositions prepared from dantrolene. In particular, the invention provides formulations for the lyophilization of dantrolene sodium. The lyophilized powder obtained from such formulations is more easily reconstituted than the presently available lyophilized powder of dantrolene.
- In one embodiment, the active pharmaceutical compounds that can be used in the present invention include dantrolene, aminodantrolene, azumolene, and salts and mixtures thereof. In one embodiment, the active pharmaceutical compounds are dantrolene sodium, 3½H2O, azumolene sodium, 2H2O and aminodantrolene sodium.
- The present invention further provides formulations of dantrolene useful for treating various disease states, especially neural diseases and malignant hyperthermia. The formulations described herein can be administered alone or in combination with at least one additional therapeutic agent.
- Another aspect of the invention is conditions and means for enhancing the solubility of dantrolene sodium during the lyophilization reconstitution process.
- As described herein, a lyophilized formulation of dantrolene sodium is achieved following removal of an organic solvent in water. The most typical example of the solvent used to prepare this formulation is alcohol. In one embodiment, the alcohol is butanol. In another embodiment, the alcohol is tertiary butanol (TBA). Other organic solvents can be used including ethanol, n-propanol, n-butanol, isoproponal, ethyl acetate, dimethyl carbonate, acetonitrile, dichloromethane, methyl ethyl ketone, methyl isobutyl ketone, acetone, 1-pentanol, methyl acetate, methanol, carbon tetrachloride, dimethyl sulfoxide, hexafluoroacetone, chlorobutanol, dimethyl sulfone, acetic acid, cyclohexane. These preceding solvents may be used individually or in combination. Useful solvents must form stable solutions with dantrolene sodium and must not react chemically or appreciably degrade or deactivate the API. The solubility of dantrolene sodium in the selected solvent must be high enough to form commercially useful concentrations of the drug in solvent. Additionally, the solvent should be capable of being removed easily from an aqueous dispersion or solution of the drug product, e.g., through lyophilization or vacuum drying. In one embodiment, a solution having a concentration of about 1-80 mg/mL is used; in another embodiment, a solution of about 0.05 to 10 mg/mL is used, in another embodiment, a solution of about 0.1 to about 3.5 mg/mL is used.
- A pharmaceutically acceptable lyophilization excipient can be dissolved in the aqueous phase during the formulation process. Examples of excipients useful for the present invention include, without limitation, sodium or potassium phosphate, citric acid, tartaric acid, gelatin, glycine, and carbohydrates such as lactose, sucrose, maltose, glycerin, dextrose, dextran, trehalose and hetastarch. Mannitol is a preferred excipient. Other excipients that may be used if desired include antioxidants, such as, without limitation, ascorbic acid, acetylcysteine, cysteine, sodium hydrogen sulfite, butyl-hydroxyanisole, butyl-hydroxytoluene or alpha-tocopherol acetate, or chelators and pH adjusting agents.
- A typical formulation and lyophilization cycle useful in accordance with the present invention is provided below. Lyophilization can be carried out using standard equipment as used for lyophilization or vacuum drying. The cycle may be varied depending upon the equipment and facilities used for the fill/finish.
- In accordance with a typical embodiment of the present invention, an aqueous pre-lyophilization solution or dispersion is first formulated in a pharmaceutically acceptable compounding vessel. The solution is aseptically filtered into a sterile container, filled into an appropriate sized vial, partially stoppered and loaded into the lyophilizer.
- In one embodiment, using lyophilization techniques described herein, the solution is lyophilized until moisture content in the range of about 0.01 to about 8.0 percent is achieved. The resulting lyophilization powder can be readily reconstituted with Sterile Water for Injection, or other suitable carrier, to provide liquid formulations of dantrolene sodium, suitable for internal administration e.g., by parenteral injection. For intravenous administration, the reconstituted liquid formulation, i.e., the pharmaceutical composition, is preferably a solution.
- In one embodiment, the method for lyophilizing the pre-lyophilization solution comprises:
- i) cooling the pre-lyophilization solution to a temperature below about −30° C., preferably below about −40° C., to form a frozen solution;
- ii) holding the frozen solution at or below −30° C., preferably at or below −40° C., more preferably at or below −50° C., for at least 1 hour, preferably for at least 2 hours; more preferably for 2-4 hours;
- iii) ramping the frozen solution to a primary drying temperature between about −45° C. and about 20° C. to form a dried solution, wherein the ramping occurs over a period of at least 1 hour, preferably for at least 2 hours; more preferably for 2-3 hours;
- iv) holding at a temperature of about 20° C. for about 10 to about 70 hours; preferably 20 to about 50 hours; more preferably about 30 to about 40 hours; most preferably from about 30 hours to about 35 hours;
- v) ramping the dried solution to a secondary drying temperature between about 25° C. and about 50° C., preferably at least 30° C., more preferably at least 35° C., most preferably at least 40° C., wherein the ramping occurs over a period of at least 30 minutes, preferably for at least 1 hour; more preferably for 1-2 hours; and
- vi) holding at the secondary drying temperature for about 1 to about 30 hours; preferably 2 to about 20 hours; more preferably about 3 to about 10 hours; most preferably from about 5 hours to about 7 hours; to form a dantrolene sodium lyophilized preparation.
- In another embodiment, the method for lyophilizing the pre-lyophilization solution further comprises the steps:
- vii) ramping the dried solution to a temperature between about 25° C. and about 40° C., preferably less than 35° C., more preferably less than 30° C., wherein the ramping occurs over a period of at least 30 minutes, preferably for at least 1 hour; more preferably for 1-2 hours; and
- viii) holding at the new temperature for at least 1 hour, preferably for at least 2 hours; more preferably for 2-4 hours; to form a dantrolene sodium lyophilized preparation.
- In one embodiment of the invention, the pressure is about 70 to about 130 microns throughout primary drying cycle, preferably the pressure is about 80 to about 120 microns throughout primary drying and more preferably from about 90 to about 110 microns throughout primary drying. In another embodiment of the invention, the pressure is about 90 to about 150 microns throughout secondary drying cycle, preferably the pressure is about 100 to about 140 microns throughout secondary drying and more preferably from about 110 to about 130 microns throughout secondary drying.
- In another embodiment, the method for lyophilizing the pre-lyophilization solution comprises:
-
- i) starting with a shelf temperature of about 25° C. for loading;
- ii) freezing to about −40 to −50° C. over about 2-4 hours;
- iii) holding at −45° C. for about 2-3 hours;
- iv) ramping to about 20° C. over about 2-3 hours;
- v) holding at about 20° C. for 30-35 hours;
- vi) ramping to about 40° C. over about 1-2 hour;
- vii) holding at about 40° C. for about 5-7 hours;
- vii) ramping to about 30° C. over about 1-2 hours; and
- ix) holding at about 30° C. for about 2-4 hrs;
- to form a dantrolene sodium lyophilized preparation.
- In one embodiment, the pre-lyophilization solution has a starting temperature above about 5° C., preferably above 15° C., to facilitate loading. In another embodiment, the pre-lyophilization solution is frozen at a temperature of about −40° C. to about −50° C., to form a frozen solution.
- In another embodiment, the pre-lyophilization solution or dispersion normally is first formulated in a pharmaceutically acceptable container by: 1) adding an excipient, such as mannitol (about 0 to about 500 mg/mL) with mixing to water at ambient temperature, 2) adding an organic solvent (0.5-99.9% v/v), such as TBA to the aqueous solution with mixing at about 20-35° C., 4) adding dantrolene sodium to the desired concentration with mixing, 5) adding water to achieve the final volume, and 6) cooling the solution to a temperature of from about 10° C. to about 30° C., preferably about 25° C. In one embodiment, the excipient may be added during a later step such as after adding the organic solvent. Although the preceding steps are shown in a certain order, it is understood that one skilled in the art can change the order of the steps and quantities as needed. Quantities can be prepared on a weight basis also.
- In another embodiment, the pre-lyophilization solution or dispersion normally is first formulated in a pharmaceutically acceptable container by: 1) adding an excipient, such as mannitol (about 0 to about 500 mg/mL) with mixing with sterile water at ambient temperature and enough sodium hydroxide (NaOH) in 100% sterile water to bring the pH to 10.1 to 10.3° C., 2) adding dantrolene sodium to the desired concentration with mixing, 3) adding sterile water to achieve the final volume, 4) heating the solution to about 40° C. to about 70° C., preferably about 45° C. to about 60° C., more preferably about 50° C. for a time sufficient to substantially solubilize the dantrolene sodium, 5) cooling the solution to about 10° C. to about 35° C., preferably to a temperature about 30° C., more preferably to a temperature less than about 30° C., more preferably to a temperature less than about 26° C., adding an organic solvent (0.5-99.9% v/v), such as TBA to the aqueous solution with mixing at about 20-35° C., and 6) cooling the solution to about 10° C. to about 30° C., preferably about 5° C. In one embodiment, the excipient may be added during a later step such as after cooling the solution in step 5) or after adding the organic solvent. Although the preceding steps are shown in a certain order, it is understood that one skilled in the art can change the order of the steps and quantities as needed. Quantities can be prepared on a weight basis also.
- The pre-lyophilization solution or dispersion can be sterilized prior to lyophilization, sterilization is generally performed by aseptic filtration, e.g., through a 0.22 micron or less filter. Multiple sterilization filters can be used. Additional sterilization of the solution or dispersion can be achieved by other methods known in the art, e.g., radiation.
- In this case, after sterilization, the solution or dispersion is ready for lyophilization. Generally, the filtered solution will be introduced into a sterile receiving vessel, and then transferred to any suitable container or containers in which the formulation may be effectively lyophilized. Usually the formulation is effectively and efficiently lyophilized in the containers in which the product is to be marketed, such as, without limitation, a vial, as described herein and as known in the art.
- A typical procedure for use in lyophilizing the pre-lyophilization solutions or dispersions is set forth below. However, a person skilled in the art would understand that modifications to the procedure or process may be made depending on such things as, but not limited to, the pre-lyophilization solution or dispersion and lyophilization equipment.
- Initially, the product is placed in a lyophilization chamber under a range of temperatures and then subjected to temperatures well below the product's freezing point, generally for several hours. In one embodiment, the product is chilled below the freezing point of the solution preferably to about −5° C., more preferably to about −10° C. or lower, even more preferably to about −20° C. or lower. In one embodiment, the temperature will be at or below about −40° C. for at least 2 hours. After freezing is complete, the chamber and the condenser are evacuated through vacuum pumps, the condenser surface having been previously chilled by circulating refrigerant. Preferably, the condenser will have been chilled below the freezing point of the solution preferably to about −40° C. In another embodiment, the condenser will have been chilled to about −45° C. or lower, in another embodiment to about −60° C. or lower. Additionally, evacuation of the chamber should continue until a pressure of about 10 to about 600 mTorr, preferably about 50 to about 150 mTorr is obtained.
- The product composition is then warmed under vacuum in the chamber and condenser. This usually will be carried out by warming the shelves within the lyophilizer on which the product rests during the lyophilization process at a pressure ranging from about 10 to about 600 mTorr. The warming process will optimally take place very gradually. In one embodiment, the warming process will take place over the course of several hours. In one embodiment, the product temperature is initially increased from about −40° C. to about 20° C. and maintained for about 10-70 hours. In another embodiment, the product temperature is initially increased from about −46° C. to about 20° C. and maintained for about 20-40 hours.
- Additionally, the product temperature can be increased to a temperature to about 25° C.-40° C. over a period of 0-20 hours.
- To prevent powder ejection of the lyophilisate from vials, complete removal of the organic solvent and water should be done during the initial drying phase. Complete drying can be confirmed by stabilization of vacuum, condenser temperature and product shelf temperature. After the initial drying, the product temperature should be increased to about 25° C.-40° C. and maintained for about 5-40 hours.
- Once the drying cycle is completed, the pressure in the chamber can be slowly released to atmospheric pressure (or slightly below) with sterile, dry-nitrogen gas (or equivalent gas). If the product composition has been lyophilized in containers such as vials, the vials can be stoppered, removed and sealed. Several representative samples can be removed for purposes of performing various physical, chemical, and microbiological tests to analyze the quality of the product.
- The lyophilized dantrolene formulation is typically marketed in pharmaceutical dosage form. The pharmaceutical dosage form of the present invention, although typically in the form of a vial, may be any suitable container, such as ampoules, syringes, co-vials, which are capable of maintaining a sterile environment. Such containers can be glass or plastic, provided that the material does not interact with the dantrolene formulation. The closure is typically a stopper, most typically a sterile rubber stopper, preferably a bromobutyl rubber stopper, which affords a hermetic seal.
- After lyophilization, the dantrolene lyophilization powder may be filled into containers, such as vials, or alternatively the pre-lyophilization solution can be filled into such vials and lyophilized therein, resulting in vials which directly contain the lyophilized dantrolene formulation. Such vials are, after filling or lyophilization of the solution therein, sealed, as with a stopper, to provide a sealed, sterile, pharmaceutical dosage form. Typically, a vial will contain a lyophilized powder including about 10-500 mg/vial, preferably about 100 mg/vial, dantrolene sodium and about 5 mg-3.0 g/vial, preferably about 3.0 g/vial, mannitol. In another embodiment, the amount of dantrolene sodium is about 5 to about 100 mg/container, about 5-50 mg/vial, about 10 mg to about 30 mg/vial and about 10 mg to about 20 mg/vial.
- The lyophilized formulations of the present invention may be reconstituted with water, preferably Sterile Water for Injection, or other substantially sterile fluid such as co-solvents, to provide an appropriate solution of dantrolene sodium for intravenous administration.
- The results shown in Table 1 indicate that dantrolene sodium solubility is dependant on temperature and the amount of alcohol in aqueous solutions. For the alcohols tested, the solubility of dantrolene sodium increased as the concentration of alcohol increased. The formation of a precipitant was also dependent on the temperature and time.
- Alcohols varied in their effect on solubility. Without wishing to be bound to any particular theory, smaller alcohols such as methanol and ethanol have less of an effect on solubility as compared with larger alcohols (tertiary-butanol and n-butanol). However, the shape of the alcohol is also important. For example tert-butanol was found to be better than iso-butanol in preventing precipitation in this system. The alcohol with the greatest effect on solubility was tertiary-butanol.
- The pharmaceutical compositions of the present invention comprise specifically defined dantrolene compounds, used in a safe and effective amount, together with a pharmaceutically acceptable carrier.
-
-
-
- in which R is from one to two substitutes selected from the group consisting of nitro, cyano, amino, chloro, bromo, acetyl, cargboxy, methyl, trifluorimethyl, and hydrogen;
X is a member of the group consisting of carbonyl and methylene; and
Y is a member of the group consisting of hydroxyethyl, butyl, hydrogen, and r-pyridylethyl.
- in which R is from one to two substitutes selected from the group consisting of nitro, cyano, amino, chloro, bromo, acetyl, cargboxy, methyl, trifluorimethyl, and hydrogen;
- In certain embodiments, the active compound is one or more of the following compounds:
- 1-[5-(p-nitrophenyl)furfurylideneamino]hydantoin;
- 1-[5-(p-aminophenyl)furfurylideneamino]hydantoin;
- 1-[5-(m-nitrophenyl)furfurylideneamino]hydantoin;
- 1-[5-(p-chlorophenyl)furfurylideneamino]hydantoin;
- 1-[5-(2,4-dichlorophenyl)furfurylideneamino]hydantoin;
- 1-[5-(2,methyl-4-nitrophenyl)furfurylideneamino]hydantoin;
- 1-[5-(p-nitrophenyl)furfurylideneaminio]-2-imidazolidinone;
- 1-[5-(p-cyanophenyl)furfurylideneamino]hydantoin;
and pharmaceutically acceptable salts thereof. - The active pharmaceutical ingredient (API) dantrolene sodium (DS) (USP) is a hemiheptahydrate salt; 1-[5-(4-nitrophenyl) furfurylidene amino]imidazolidine-2,4-dione, containing 14.5-17.0% of water (3½ moles) and has a molecular weight of 399. The anhydrous salt has a molecular weight of 336.
- Dantrolene sodium (USP) is an orange, odorless powder with a melting point of 279-280° C. It is completely soluble in propylene glycol, slightly soluble in ethanol and methanol, and is insoluble in H2O (15 mg/L). Higher solubility in water at pH 8.0 or greater is exhibited by dantrolene sodium. Its free acid form (dantrolene) is totally insoluble (mg/L), and it is a weak acid with a pKa of about 7.5. However, the extremely low solubility of the free acid prevents an accurate determination of its pKa. The FDA approved lyophilized dantrolene sodium for intravenous injection (DS-IV) product (USP 2007) contains 20 mg of hydrated DS (API)(16.8 mg on the anhydrous basis), 3.0 grams of mannitol and enough NaOH to achieve a pH=9.5 (approximately) upon reconstitution with 60 mL of water for injection. The reconstituted product is administered as a rapid infusion to patients exhibiting the life-threatening condition of thermal hyperthermia during surgery.
-
- Dantrolene is an antagonist of the type 3 ryanodine receptor and is commonly given as the sodium salt (sodium dantrium), which is hydrated 1-[[[5-(4-nitrophenyl)-2-furanyl]methylene]amino]-2,4-imidazolidinedione sodium salt. Dantrolene is prescribed in the treatment of clinical spasticity resulting from upper motor neuron disorders such as spinal chord injury, cerebral palsy, stroke, or multiple sclerosis. Dantrolene is also effective in reversing the hypermetabolic process of malignant hyperthermia, a genetic disorder of skeletal muscle that is triggered by exposure to anesthetics and certain relaxants.
- Other therapeutic uses for dantrolene are known in the art. For example, Dreyer, U.S. Pat. No. 5,597,809, teaches the use of NMDA-receptor antagonists, and also dantrolene, for the treatment of optic neuritis. U.S. Pat. No. 5,506,231 to Lipton teaches the use of dantrolene for the treatment of three conditions specifically associated with AIDS: dementia, myelopathy, and blindness. Dantrolene has been used clinically to treat malignant hypothermia, as it is known to reduce cellular energy requirements, creating a hypothermic environment. Kiyoshi (Patent Abstracts of Japan (1994), publication number 06263636) discloses the use of dantrolene for treatment of cerebral nerve diseases such as geriatric dementia, Parkinson's disease and Huntington's disease.
- Non-therapeutic uses for dantrolene include cryopreservation of blood vessels. See U.S. Pat. Nos. 5,158,867; 5,149,621; 5,145,769 and 5,122,110, incorporated herein in their entirety.
- Tertiary butyl alcohol (TBA) possesses favorable properties to be utilized in aqueous co-solvent systems for the freeze-drying of pharmaceutical products. The favorable physical properties of TBA include its high vapor pressure, low melting point (freezes completely in most freeze dryers with low expenditure of energy) and readily sublimes (increases sublimation rates) during the primary drying stage of the freeze-drying process. Added to these desirable physical properties, TBA possesses low toxicity as an organic solvent (permissible residual limit about the same as ethyl alcohol, i.e. <5,000 ppm).
TABLE 2 Physicochemical properties of TBA Property Value Formula: C4 H10 O Glass Transition −93° C. Melting Point 25° C. Boiling Point 84.6 ± 8.0° C. Density 0.804 ± 0.06 g/cm3 Enthalpy of Vaporization 37.89 ± 6.0 kJ/mol Molecular Weight 74.12 pKa 15.37 ± 0.29 - Without wishing to be bound by theory, the utilization of a TBA-aqueous co-solvent system into the DS-IV formulation appears to lead to the following beneficial results:
- i. It substantially reduces the freezing time of the “fill solution” (solution that is introduced into the vials) of the formulation.
- ii. It causes an approximate two-fold decrease in the drying time of the freeze-dried cake of the DS-IV product in the course of its production.
- iii. It substantially reduces the reconstitution time of the freeze-dried (lyophilized) DS-IV product from minutes to less than 60, 50, 40, 30, 20, 10 or fewer seconds. This provides a significant improvement in the pharmacotherapy of patients exhibiting the life-threatening condition of malignant hyperthermia during surgery.
- The following Examples are provided to illustrate certain aspects of the present invention and to aid those of skill in the art in practicing the invention. These Examples are in no way to be considered to limit the scope of the invention in any manner.
- In one embodiment, the DS-IV product is a lyophilized (freeze-dried) powder containing approximately 16.8 mg of anhydrous dantrolene sodium (API) (DS) (equivalent to 20 mg of hydrous DS (API) containing 14.5% to 18% of moisture), 3 g of mannitol and enough NaOH to achieve a pH value of approximately 8.8 to 10.9 upon reconstitution with 60 mL of water for injection (WFI) per vial.
- Without wishing to be bound by theory, it is believed that due to the fact that DS (API) is highly insoluble, it must be dissolved at an alkaline environment (above its pKa 7.4 value). Since DS is susceptible to an alkaline hydrolysis, it must be dissolved as rapidly as possible during its formulation step. To achieve a rapid dissolution of DS, higher temperatures have to be utilized. The alkalinity (pH value), temperature and duration of heating of the liquid DS formulation play a role in the strength (percent of API) of the final lyophilized DS-IV product. The conditions may be appropriately adjusted to achieve a favorable strength (94-97%) in the final product.
- It is known that an aqueous co-solvent system may be used to facilitate the dissolution of an insoluble drug. When an aqueous co-solvent system consisting of 5%, 10% and 20% TBA was used in the DS formulation, the drug (DS) (API) remained unsolubilized even after 90 minutes of mixing time at room temperature. Surprisingly, the addition of TBA to the aqueous portion of the DS formulation did not increase the solubilization rate of DS (API) as is the case with the majority of drug formulations in which the TBA-aqueous co-solvent system is used. However, it was discovered that the use of the TBA shortened the freezing time of the pre-lyophilized “fill” solution, the freeze-drying time and the reconstitution of the freeze-dried cake of the DS-IV product.
-
FIG. 1 shows the preferred manner by which solubilization of DS is achieved if the API (DS) is first mixed with its formulation constituents (e.g., about 3 g of mannitol and enough of NaOH in 100% sterile water to bring the pH to about 8.8 to about 11, preferably, from about 10 to about 10.5, more preferably from about 10.1 to about 10.3) at about 50° for a period of about 20 minutes. - This is followed by a period of cooling (about 45-60 min) down to about 25° C. The TBA is subsequently added at about 25° C. (See
FIG. 1 ) to complete the formulation process. Importantly, the addition of TBA at about 25° C. does not cause any undesirable loss of the strength (percent of API) of the formulation. This is substantiated by the fact that when the TBA-treated formulation was freeze-dried, the final reconstituted product of DS-IV exhibited strength of 95±1% (See Table 3).TABLE 3 Summary of percent (%) assay of DS-IV vials TBA % Assay % 0 95.94 ± 0.54 5 96.40 ± 0.60 10 94.66 ± 0.24 20 96.22 ± 0.70
The Impact of TBA on the Freeze-Drying Process of DS-IV Formulation - In general, the presence of TBA solvent affects the freezing characteristics of a solution. Furthermore, it significantly impacts the crystal morphology of the ice, the drying rates, the surface area of the dried cake and reconstitution times of lyophilisates (freeze-dried cake) [2].
- The size and shape of the ice crystals depend on the nature and quantity of the organic solvents used in co-solvent system. Thermal analysis studies have been used to evaluate the various stable and metastable states which form with TBA-water systems during freezing. Adding TBA at different ratios was found to cause the formation of large needle-shaped ice crystals, which when sublimed they created a more porous and less resistant matrix which facilitated the drying process. Thus, drying times can be decreased by approximately 30-50% [3].
- Impact of TBA on Sublimation Rates
- Improvements in the rate of mass transfer of a solvent through a partially dried cake layer increases the sublimation rate and hence it decreases the time for the primary drying phase of the freeze-dry cycle. This leads in the overall reduction of the freeze-drying process which translates in considerable savings in energy and cost of product manufacturing.
- Reduction in Drying Time and Freezing Time of DS-IV Product Cake
- The present invention reveals that the introduction of about 2% to about 20% TBA into the DS-IV formulation results in an approximate two-fold reduction in drying time of its lyophilisate. The increased drying rate is probably caused by the formation of needle-shaped ice crystals which create a porous structure, which in turn facilitate the mass transfer of water vapor due to decreased cake resistance and the increase in its surface area.
- A typical example of freeze-drying cycle of DS-IV product, produced with about 5% TBA aqueous co-solvent system, comprises of the following segments: 1) starting with a shelf temperature of about 25° C. for loading; 2) freezing to about −40 to −50° C. over about 2-4 hours; 3) holding at −45° C. for about 2-3 hours; 4) ramping to about 20° C. over about 2-3 hours; 5) holding at about 20° C. for 30-35 hours; 6) ramping to about 40° C. over about 1-2 hour; 7) holding at about 40° C. for about 5-7 hours; 8) ramping to about 30° C. over about 1-2 hours; 9) holding at about 30° C. for about 2-4 hrs. The pressure is about 90-110 microns throughout primary drying and 110-130 microns throughout secondary drying.
- Compared to the original freeze drying cycle (with no TBA), the addition of TBA in the DS-IV formulation, has reduced the total freeze-drying cycle duration by 33% (i.e., from 75 hours to about 50 hours or less).
- Enhancement in the Reconstitution Time of the Lyophilized DS-IV Product by TBA
- Due to the increased porous structure of the DS-IV lyophilized product which was created by the introduction of TBA, the reconstitution time of the DS-UV product was decreased from 1 to 3 minutes per vial to less than 10 seconds (See Table 4). This almost instantaneous reconstitution of the DS-IV lyophilized powder constitutes a significant improvement in the treatment of patients with malignant hyperthermia. The recommended DS dose for treatment of MH ranges from 1 mg/kg to 10 mg/kg. If we consider that each vial containing 0.02 g of DS (API), then the above recommended doses translate to a minimum of four (4) vials to a maximum of 36 vials per MH episode. The Merck Manual (18th edition, 2006) recommends a treatment for MH that starts with 2.5 mg/kg (9-10 vials). It is also recommended that treatment should be initiated immediately after symptoms of MH develop. On the average, patients exhibiting MH require a rapid intravenous (IV) infusion of nine to ten (9-10) (2.5 mg/kg) vials of DS-IV product, each reconstituted with 60 mL of sterile water for injection (WFI). In many cases, the number of DS-IV vials used ranges from 10-20. Cases of MH requiring as many as 36 vials of DS-IV have been recorded. The length of time to reconstitute 10-36 vials (1 to 3 min each required for reconstitution) creates an issue when considering death due to MH can occur in as short time as 30 min from onset. In adult patients, temperatures exceeding 41° C. (105.8° F.) could prove fatal in periods of MH exceeding 30 min (Merck Manual, 18th Edition, 2006).
TABLE 4 Reconstitution times of DS-IV product before and after utilization of the TBA-aqueous co-solvent system TBA % Time (sec) 0 <90 5 <10 10 <10 20 <10 - It has now been discovered that dantrolene sodium prevents or reduces arrhythmia in hypothermic and normothermic warm-blooded animals. In particular, dantrolene sodium is effective in the treatment of supraventricular tachycardias, in suppressing slow responses in infarcted tissues and in abolishing ventricular premature beats or tachycardias originating in these tissues, and in correcting ventricular rhythm disturbances due to reentry.
- In addition, information regarding procedural or other details supplementary to those set forth herein is described in cited references specifically incorporated herein by reference.
- It would be obvious to those skilled in the art that modifications or variations may be made to the preferred embodiment described herein without departing from the novel teachings of the present invention. All such modifications and variations are intended to be incorporated herein and within the scope of the claims.
-
- 1. Practical aspects of lyophilization using non-aqueous co-solvent systems. Dirk L. Teagarden, and David S. Baker. Department of Sterile Products Development, Pharmacia Corporation, 7000 Portage Road, Kalamazoo, Mich. 49001-0199, USA
- 2. The effect of tertiary butyl alcohol on the resistance of the dry product layer during primary drying. Pharmaceutical Research, Kasra Kasraian and Patrick DeLuca. 12 (4), 491-495, 1995
- 3. Thermal analysis of the tertiary butyl alcohol-water system and its implications on freeze-drying. Pharmaceutical Research, Kasra Kasraian and Patrick DeLuca. 12 (4), 484-490, 1995
- 4. Freeze-drying of tertiary butanol/water co-solvent systems: a case report on formation of friable freeze-dried powder of tobramycine sulfate. Journal of Pharmaceutical Sciences. Wittaya-Areekul Sackchai et. al. 91(4), 1147-55, 2002
Claims (41)
1. A pharmaceutical composition comprising: (a) an aqueous solvent; and (b) an organic co-solvent; and (c) at least one active pharmaceutical compound having the formula:
wherein
A has the formula
in which R is from one to two substitutes selected from the group consisting of nitro, cyano, amino, chloro, bromo, acetyl, cargboxy, methyl, trifluorimethyl, and hydrogen;
X is a member of the group consisting of carbonyl and methylene; and
Y is a member of the group consisting of hydroxyethyl, butyl, hydrogen, and r-pyridylethyl.
2. The pharmaceutical composition of claim 1 wherein the active pharmaceutical compound is selected from the group consisting of 1-[5-(p-nitrophynyl) furfurylideneamino]hydantoin, 1-[5-(p-aminophenyl)furfurylideneamino]hydantoin, 1-[5-(p-chlorophenyl)furfurylideneamino]hydantoin, 1-[5-(2,4-dichlorophenyl)furfurylideneamino]hydantoin, 1-[5-(2,4-dichlorophenyl)furfurylideneamino]hydantoin, 1-[5-(2,methyl-(p-nitrophenyl)furfurylideaneamino]hydantoin, 1-[5-(p-nitrophenyl)furfurylideneaminio]-2-imidazolidinone, and 1-[5-(p-cyanophenyl)furfurylideneamino]hydantoin.
3. A pharmaceutical composition comprising: (a) an aqueous solvent; and (b) an organic co-solvent; and (c) dantrolene sodium as an active pharmaceutical compound.
4. The composition of claim 1 wherein the organic co-solvent is selected from the group consisting of tertiary butyl alcohol (TBA), n-propanol, n-butanol, isopropanol, ethanol, methanol, acetone, ethyl acetate, dimethyl carbonate, acetonitrile, dichloromethane, methyl ethyl ketone, methyl isobutyl ketone, 1-pentanol, methyl acetate, carbon tetrachloride, dimethyl sulfoxide, hexafluoroacetone, chlorobutanol, dimethyl sulfone, acetic acid, and cyclohexane, ethyl acetate, acetone, dimethylsulfoxide, chlorobutanol, acetic acid and mixtures thereof.
5. A stable and lyophilized formulation of dantrolene sodium made by the process comprising a) dissolving dantrolene sodium in an alkaline solution of water and organic co-solvent solution comprising between about 1% to about 99% (v/v) organic co-solvent to form a pre-lyophilization solution; and b) lyophilizing the pre-lyophilization solution.
6. The stable and lyophilized formulation of claim 5 wherein the residual concentration of organic co-solvent in the final lyophilized product is less than about 0.5%.
7. The stable and lyophilized formulation of claim 5 wherein the concentration of DS degradants in the final lyophilized product is less than about 8%.
8. The lyophilized preparation according to claim 5 , wherein the preparation is packaged in a vial or other pharmaceutically acceptable container.
9. The lyophilized preparation according to claim 6 , wherein the preparation is substantially stable with respect to the amount of DS-IV for at least about six months when stored at 5° C.
10. A pharmaceutical unit dosage form comprising a pharmaceutical composition of dantrolene sodium formed by the reconstitution of the lyophilized preparation of claim 5 .
11. A pharmaceutical dosage form of claim 10 , wherein the pharmaceutical dosage form comprises about 10 mg to about 30 mg of dantrolene sodium.
12. A pharmaceutical dosage form of claim 10 , wherein the pharmaceutical dosage form comprises about 15 mg to about 25 mg of dantrolene sodium.
13. A pharmaceutical dosage form of claim 10 , wherein the pharmaceutical dosage form comprises a trace amount of one or more organic solvents,
14. A pharmaceutical composition of dantrolene sodium according to claim 13 wherein the organic solvent is selected from the group consisting of one or more of tertiary butanol, n-propanol, n-butanol, isopropanol, ethanol, methanol, acetone, ethyl acetate, dimethyl carbonate, acetonitrile, dichloromethane, methyl ethyl ketone, methyl isobutyl ketone, 1-pentanol, methyl acetate, carbon tetrachloride, dimethyl sulfoxide, hexafluoroacetone, chlorobutanol, dimethyl sulfone, acetic acid, and cyclohexane.
15. A pharmaceutical composition of dantrolene sodium according to claim 13 wherein the organic solvent is selected from the group consisting of one or more of ethanol, methanol, propanol, butanol, isopropanol, and tertiary butanol.
16. A pharmaceutical composition according to claim 15 , wherein the organic solvent is tertiary butanol.
17. A method of preparing a dantrolene sodium lyophilized preparation comprising, a) dissolving dantrolene sodium in a stabilizing concentration of an alcohol solvent comprising between about 1% to about 99.99% (v/v) alcohol to form a pre-lyophilization solution; and b) lyophilizing the pre-lyophilization solution.
18. A method according to claim 17 , wherein the alcohol concentration is between about 1% to about 99.9%.
19. A method according to claim 17 , wherein the alcohol is selected from one or more of methanol, ethanol, propanol, iso-propanol, butanol, and tertiary-butanol.
20. A method according to claim 19 , wherein the alcohol is tertiary-butanol.
21. A method according to claim 20 , wherein the tertiary butanol is at a concentration of about 1% to 99.9%.
22. A method according to claim 17 , wherein an excipient and a pH adjusting agent are added before lyophilization.
23. A method according to claim 22 , wherein the excipient comprises mannitol and sodium hydroxide.
24. A method according to claim 23 , wherein the dantrolene sodium concentration is about 0.1 to about 1 mg/mL.
25. The lyophilized powder obtained from the method according to claim 24 .
26. A method according to claim 17 wherein step b) comprises: i) freezing the pre-lyophilization solution to a temperature below about −40° C. to form a frozen solution; ii) holding the frozen solution at or below −40° C. for at least 2 hours; iii) ramping the frozen solution to a primary drying temperature between about −40° C. and about 20° C. to form a dried solution; iv) holding for about 10 to about 70 hours; v) ramping the dried solution to a secondary drying temperature between about 25° C. and about 40° C.; and vii) holding for about 5 to about 40 hours to form a dantrolene sodium lyophilized preparation.
27. A method according to claim 26 , wherein the alcohol is tertiary-butanol.
28. A method according to claim 27 , wherein the tertiary butanol is at a concentration of about 1% to 30%.
29. The lyophilized powder obtained from the method according to claim 28 .
30. A method according to claim 17 further comprising, prior to step a), the step of dissolving the dantrolene sodium in an aqueous solution at elevated temperatures.
31. A method according to 31, wherein the aqueous solution is heated the solution to a temperature of about 40° C. to about 70° C., for a time sufficient to substantially solubilize the dantrolene sodium.
32. A method according to 32, further comprising the step of cooling the aqueous solubilized dantrolene solution to a temperature about 15° C. to about 30° C. prior to adding the alcohol solvent.
33. A formulation for lyophilization comprising dantrolene sodium at a concentration of about 0.1 to about 5 mg/mL, mannitol at a concentration of about 2 to about 100 mg/mL, tertiary-butyl alcohol at a concentration of about 1 to about 99% (v/v) and an amount of aqueous alkaline solution adequate to adjust the pH at a range of from about 9.5 to about 10.5.
34. A lyophilized preparation made from the method according to claim 33 .
35. A method of treating a medical condition in a patient comprising dissolving the preparation of claim 34 in a pharmaceutically acceptable carrier to produce a pharmaceutically acceptable solution and administering to the patient a therapeutically effective amount of the solution, wherein the condition is amenable to treatment with the preparation.
36. A method of treating according to claim 35 , wherein the condition is malignant hyperthermia.
37. A method of treating according to claim 36 further comprising administering the dissolved preparation of claim 34 in combination with one or more additional active agents wherein the additional agent is given prior, concurrently, or subsequent to the administration of the preparation of claim 34 .
38. A method of treating according to claim 37 wherein the additional agent is.
39. A pharmaceutical dosage form according to claim 8 , wherein the vial or other pharmaceutically acceptable container contains dantrolene sodium at a concentration of about 10 to about 500 mg/container.
40. A dantrolene sodium pre-lyophilization solution or dispersion comprising dantrolene sodium, between about 1% to about 99.9% (v/v) alcohol, excipient and water
41. A pre-lyophilization solution or dispersion of dantrolene sodium comprising dantrolene sodium, mannitol, tertiary-butyl alcohol, and alkalinized sterile water and having a pH in the range of about 9.5 to about 10.5.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12/205,303 US8975284B2 (en) | 2007-10-09 | 2008-09-05 | Co-solvent compositions and methods for improved delivery of dantrolene therapeutic agents |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US97862607P | 2007-10-09 | 2007-10-09 | |
US12/205,303 US8975284B2 (en) | 2007-10-09 | 2008-09-05 | Co-solvent compositions and methods for improved delivery of dantrolene therapeutic agents |
Publications (5)
Publication Number | Publication Date |
---|---|
US20090093531A1 US20090093531A1 (en) | 2009-04-09 |
US20110015243A2 US20110015243A2 (en) | 2011-01-20 |
US20110160261A9 US20110160261A9 (en) | 2011-06-30 |
US20110160261A2 true US20110160261A2 (en) | 2011-06-30 |
US8975284B2 US8975284B2 (en) | 2015-03-10 |
Family
ID=40316940
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/205,303 Active 2031-09-23 US8975284B2 (en) | 2007-10-09 | 2008-09-05 | Co-solvent compositions and methods for improved delivery of dantrolene therapeutic agents |
Country Status (6)
Country | Link |
---|---|
US (1) | US8975284B2 (en) |
EP (2) | EP2219605B1 (en) |
JP (1) | JP5406197B2 (en) |
CA (1) | CA2702243C (en) |
ES (1) | ES2583804T3 (en) |
WO (1) | WO2009048698A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20140072525A1 (en) * | 2012-09-07 | 2014-03-13 | Gaab, Llc | Antimicrobial preparation and methods for making and using the same |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2665902A1 (en) * | 2006-10-03 | 2008-04-10 | Wyeth | Lyophilization methods and apparatuses |
US8536213B2 (en) * | 2007-11-16 | 2013-09-17 | Nektar Therapeutics | Oligomer-dantrolene conjugates and related compounds |
US20120040970A1 (en) * | 2009-04-27 | 2012-02-16 | Al-Ghananeem Abeer M | Intranasal delivery system for dantrolene |
US9102645B2 (en) | 2013-03-15 | 2015-08-11 | Rosalind Franklin University Of Medicine And Science | Compounds for stabilizing ryanodine receptors from aberrant levels of calcium release |
US9725429B2 (en) | 2013-03-15 | 2017-08-08 | Rosalind Franklin University Of Medicine And Science | Furanyl-imine and thiofuranyl-imine compounds for stabilizing ryanodine receptors from aberrant levels of calcium release |
WO2015157212A1 (en) * | 2014-04-10 | 2015-10-15 | Us Worldmeds, Llc | Stable apomorphine composition and uses thereof |
CN118078742A (en) * | 2015-10-20 | 2024-05-28 | 斯帕方有限公司 | Aqueous compositions comprising dantrolene |
WO2018236793A1 (en) * | 2017-06-20 | 2018-12-27 | Tarveda Therapeutics, Inc. | Targeted therapeutics |
JP7252963B2 (en) * | 2017-10-20 | 2023-04-05 | イーグル リサーチ ラブズ リミテッド | Dantrolene products and methods of their use |
WO2019175761A1 (en) * | 2018-03-12 | 2019-09-19 | Orbicular Pharmaceutical Technologies Private Limited | Ready to use dantrolene compositions |
EP3773488A4 (en) * | 2018-04-05 | 2021-11-17 | Tarveda Therapeutics, Inc. | Pharmaceutical compositions with reduced tert-butanol levels |
WO2020049670A1 (en) * | 2018-09-06 | 2020-03-12 | シミックホールディングス株式会社 | Dantrolene aqueous formulation and method for preparing same |
WO2022169582A1 (en) * | 2021-02-05 | 2022-08-11 | Uswm, Llc | Compositions and methods for clear concentrated parenteral delivery of dantrolene therapeutic agents |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3415821A (en) | 1965-09-07 | 1968-12-10 | Norwich Pharma Co | 1-(5-substituted)furfurylideneamino hydantoins and imidazolidinones |
US4543359A (en) | 1982-10-01 | 1985-09-24 | Eaton Laboratories, Inc. | Treating cardiac arrhythmias with dantrolene sodium |
US5149621A (en) | 1987-08-21 | 1992-09-22 | Cryolife, Inc. & Medical Univ. Of South Carolina | Kit for cryopreserving blood vessels |
US5145769A (en) | 1987-08-21 | 1992-09-08 | Cryolife Inc. | Method for cryopreserving blood vessels |
US5158867A (en) | 1987-08-21 | 1992-10-27 | Cryolife Inc. | Method for cryopreserving blood vessels |
JPH01128923A (en) * | 1987-11-11 | 1989-05-22 | Mikasa Seiyaku Kk | Skeletal muscle relaxing external preparation |
US5506231A (en) | 1989-03-31 | 1996-04-09 | The Children's Medical Center Corporation | Treatment of aids dementia, myelopathy and blindness |
AU5015193A (en) * | 1992-09-09 | 1994-03-29 | Washington University | Prevention or treatment of sepsis with dantrolene or azumolene |
JPH06263636A (en) * | 1993-03-12 | 1994-09-20 | Kiyoshi Kataoka | Therapeutic agent for cerebral or higher nervous disease |
US5733900A (en) | 1994-04-21 | 1998-03-31 | Hisamitsu Pharmaceutical Co., Inc. | Percutaneous administration base composition and percutaneous administration medicinal composition comprising said base composition and medicine |
US5597809A (en) | 1994-06-23 | 1997-01-28 | Massachusetts Eye & Ear Infirmary | Treatment of optic neuritis |
US7758890B2 (en) * | 2001-06-23 | 2010-07-20 | Lyotropic Therapeutics, Inc. | Treatment using dantrolene |
EP1435781A4 (en) * | 2001-06-23 | 2007-06-20 | Lyotropic Therapeutics Llc | Solvent system |
AU2004262507B2 (en) * | 2003-03-04 | 2010-02-18 | Lyotropic Therapeutics, Inc. | Treatment using dantrolene |
US8436190B2 (en) | 2005-01-14 | 2013-05-07 | Cephalon, Inc. | Bendamustine pharmaceutical compositions |
US8158152B2 (en) * | 2005-11-18 | 2012-04-17 | Scidose Llc | Lyophilization process and products obtained thereby |
AR072777A1 (en) | 2008-03-26 | 2010-09-22 | Cephalon Inc | SOLID FORMS OF BENDAMUSTINE CHLORHYDRATE |
-
2008
- 2008-09-05 EP EP08837079.6A patent/EP2219605B1/en active Active
- 2008-09-05 US US12/205,303 patent/US8975284B2/en active Active
- 2008-09-05 CA CA2702243A patent/CA2702243C/en active Active
- 2008-09-05 EP EP12187466.3A patent/EP2583670A1/en not_active Withdrawn
- 2008-09-05 WO PCT/US2008/075406 patent/WO2009048698A1/en active Application Filing
- 2008-09-05 ES ES08837079.6T patent/ES2583804T3/en active Active
- 2008-09-05 JP JP2010528917A patent/JP5406197B2/en active Active
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20140072525A1 (en) * | 2012-09-07 | 2014-03-13 | Gaab, Llc | Antimicrobial preparation and methods for making and using the same |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8975284B2 (en) | Co-solvent compositions and methods for improved delivery of dantrolene therapeutic agents | |
US20110160261A2 (en) | Co-solvent compositions and methods for improved delivery of dantrolene therapeutic agents | |
US20110042247A1 (en) | Formulations of azacitidine and its derivatives | |
US11766405B2 (en) | Process for the preparation of a freeze-dried pharmaceutical composition containing mitomycin C | |
US20140142153A1 (en) | Bendamustine formulations | |
KR102459213B1 (en) | Pharmaceutical Parenteral Formulations Containing Carglumic Acid | |
US20160143911A1 (en) | Stable and water soluble pharmaceutical compositions comprising pemetrexed | |
BRPI0719096A2 (en) | STABLE PARENTAL FORMULATION CONTAINING AN RSV INHIBITOR OF A BENZODIAZEPINA STRUCTURE | |
EP0833640B1 (en) | Pharmaceutical composition containing lamotrigine | |
US20120283304A1 (en) | Formulations of Temozolomide for Parenteral Administration | |
KR100807650B1 (en) | FREEZE-DRIED PREPARATION OF N-[o-p-PIVALOYLOXYBENZENESULFONYLAMINOBENZOYL]GLYCINE MONOSODIUM SALT TETRAHYDRATE AND PROCESS FOR PRODUCING THE SAME | |
WO2021208910A1 (en) | Polymer preparation for treating virus infection, and preparation method therefor and use thereof | |
JP2002508330A (en) | Pharmaceutical compositions and preparations based on dalfopristin and quinupristin | |
US20060153920A1 (en) | Lyophilized pharmaceutical compositions | |
CN111789818B (en) | Papaverine hydrochloride pharmaceutical composition for injection and preparation method thereof | |
WO2021028842A1 (en) | A stable ready-to-use injectable composition of gemcitabine or its salt and methods for producing same | |
JP2023516957A (en) | Daptomycin preparation | |
WO2022169582A1 (en) | Compositions and methods for clear concentrated parenteral delivery of dantrolene therapeutic agents | |
CN113491668B (en) | Pharmaceutical composition preparation for injection and preparation method and application thereof | |
US20060068008A1 (en) | Lyophilized pharmaceutical compositions | |
WO2005123137A2 (en) | Lyophilized pharmaceutical composition comprising moxifloxacin hydrochloride | |
CZ20003208A3 (en) | Pharmaceutical preparations containing sodium [[3-(2-amino-1,2-dioxoethyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]acetate inhibitor of phospholipase |